<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Hepatol</journal-id><journal-id journal-id-type="publisher-id">WJH</journal-id><journal-title-group><journal-title>World Journal of Hepatology</journal-title></journal-title-group><issn pub-type="epub">1948-5182</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6354117</article-id><article-id pub-id-type="other">jWJH.v11.i1.pg1</article-id><article-id pub-id-type="doi">10.4254/wjh.v11.i1.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Desai</surname><given-names>Aakash</given-names></name><aff>Department of Internal Medicine, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH 44109, United States</aff></contrib><contrib contrib-type="author"><name><surname>Sandhu</surname><given-names>Sonia</given-names></name><aff>Department of Hematology and Oncology, Cleveland Clinic/Akron General Medical Center, Akron, OH 44307, United States</aff></contrib><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Jin-Ping</given-names></name><aff>Department of Pathology, University of Florida, Gainsville, FL 32611, United States</aff></contrib><contrib contrib-type="author"><name><surname>Sandhu</surname><given-names>Dalbir Singh</given-names></name><aff>Division of Gastroenterology and Hepatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH 44109, the United States. <email>drdalbir@gmail.com</email></aff></contrib></contrib-group><author-notes><fn><p>Author contributions: Desai A, Sandhu S, Lai JP and Sandhu DS contributed to the conception and design of the study; Desai A and Sandhu DS contributed to literature review and analysis; Desai A and Sandhu S, Sandhu DS contributed to the drafting of manuscript; Sandhu S and Lai JP contributed to critical revision and editing; all authors equally contributed to approval of the final version.</p><p>Corresponding author: Dalbir Singh Sandhu, MD, Assistant Professor, Division of Gastroenterology and Hepatology, Case Western Reserve University/MetroHealth Medical Center, 2500 Metrohealth Drive, Cleveland, OH 44109, United States. <email>drdalbir@gmail.com</email></p><p>Telephone: +1-216-7785736 Fax: +1-216-7782074</p></fn></author-notes><pub-date pub-type="ppub"><day>27</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>27</day><month>1</month><year>2019</year></pub-date><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>18</lpage><history><date date-type="received"><day>24</day><month>8</month><year>2018</year></date><date date-type="rev-recd"><day>4</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><p>Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which in turns accounts for the sixth most common cancer worldwide. Despite being the 6<sup>th</sup> most common cancer it is the second leading cause of cancer related deaths. HCC typically arises in the background of cirrhosis, however, about 20% of cases can develop in a non-cirrhotic liver. This particular subgroup of HCC generally presents at an advanced stage as surveillance is not performed in a non-cirrhotic liver. HCC in non-cirrhotic patients is clinically silent in its early stages because of lack of symptoms and surveillance imaging; and higher hepatic reserve in this population. Interestingly, F3 fibrosis in non-alcoholic fatty liver disease, hepatitis B virus and hepatitis C virus infections are associated with high risk of developing HCC. Even though considerable progress has been made in the management of this entity, there is a dire need for implementation of surveillance strategies in the patient population at risk, to decrease the disease burden at presentation and improve the prognosis of these patients. This comprehensive review details the epidemiology, risk factors, clinical features, diagnosis and management of HCC in non-cirrhotic patients and provides future directions for research.</p></abstract><kwd-group><kwd>Hepatocellular carcinoma</kwd><kwd>Non-cirrhotic liver</kwd><kwd>Hepatitis B</kwd><kwd>Hepatitis C</kwd><kwd>Risk factors</kwd><kwd>Clinical features</kwd><kwd>Diagnostic modalities</kwd><kwd>Management strategies</kwd><kwd>Future directions</kwd></kwd-group></article-meta></front><body><p><bold>Core tip:</bold> Hepatocellular carcinoma (HCC) is the 2<sup>nd</sup> leading cause of cancer related deaths. Majority of HCC arise in a cirrhotic liver, however, 20% of cases can develop in non-cirrhotic liver. This comprehensive review focuses on risk factors, clinical features, diagnostic modalities, management strategies and future directions for HCC in non-cirrhotic liver.</p><sec><title>INTRODUCTION</title><p>Primary liver cancer is the sixth most common cancer worldwide, 90% of which are hepatocellular carcinoma (HCC)[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. HCC is the second leading cause of cancer-related deaths worldwide[<xref rid="B3" ref-type="bibr">3</xref>]. Although, most of the cases occur in developing countries, its incidence in developed countries has increased recently[<xref rid="B4" ref-type="bibr">4</xref>]. HCC typically arises in the setting of cirrhosis however; approximately 20% of HCC&#x02019;s have been known to develop in a non-cirrhotic liver[<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>]. This sub-group of HCC often presents at advanced stages because surveillance is not performed in a non-cirrhotic liver. Fibrolamellar carcinoma (FLC), a rare variant of HCC also occurs without any background cirrhosis or hepatitis[<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>]. This review discusses the epidemiology, risk factors, clinical features, diagnosis and management of HCC in non-cirrhotic patients as well as provides future direction for research in this population.</p></sec><sec><title>LITERATURE SEARCH</title><p>A comprehensive literature search was performed and research papers regarding non-cirrhotic HCC and related literature was analyzed to prepare this review article. Special emphasis was placed on research related to the diagnosis and management of non-cirrhotic HCC in the last 5 yr.</p></sec><sec><title>EPIDEMIOLOGY</title><p>Worldwide, liver cancer is the fifth most common cancer in men and the ninth in women. It is the 2<sup>nd</sup> leading cause of cancer death in men and the sixth leading among women, with about 745500 deaths in 2012. In the United States, there is expected to be an estimated 42220 new cases and 30200 death cases of liver and intrahepatic bile duct carcinomas in 2018[<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>]. HCC is a little over 2 times more likely in men over women, the incidence being 5.5 per 100000 in male and 2 per 100000 in female in the United States[<xref rid="B8" ref-type="bibr">8</xref>]. Non-cirrhotic HCC has a bimodal age distribution, peaking during the 2<sup>nd</sup> and 7<sup>th</sup> decade of life[<xref rid="B5" ref-type="bibr">5</xref>]. The FLC variant comprises 1%-9% of all HCC and accounts for less than 1% of HCC in the United States[<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>]. Overall, there is a lack of significant data on HCC that arises in non-cirrhotic liver. Given that HCC is one of the fastest growing cause of cancer-related deaths and has a survival rate of less than 12% in the United States, there is a need for further research to explore the epidemiology of non-cirrhotic HCC[<xref rid="B8" ref-type="bibr">8</xref>].</p></sec><sec><title>RISK FACTORS</title><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Incidence of different risk factors for hepatocellular carcinoma in cirrhotic and non-cirrhotic liver in various studies</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><bold>Parameter</bold></td><td rowspan="1" colspan="1"><bold>Study</bold></td><td rowspan="1" colspan="1"><bold>No (NC)</bold></td><td rowspan="1" colspan="1"><bold>No (CL)</bold></td><td rowspan="1" colspan="1"><bold>Percentage (NC)</bold></td><td rowspan="1" colspan="1"><bold>Percentage (CL)</bold></td><td rowspan="1" colspan="1"><bold>Mean Incidence (NC)</bold></td><td rowspan="1" colspan="1"><bold>Mean Incidence (CL)</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">Alcohol</td><td rowspan="1" colspan="1">Sch&#x000fc;tte et al[<xref rid="B16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">285</td><td rowspan="1" colspan="1">15%</td><td rowspan="1" colspan="1">50%</td><td rowspan="1" colspan="1">21.77%</td><td rowspan="1" colspan="1">30%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Nzeako et al[<xref rid="B52" ref-type="bibr">52</xref>]</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1">7%</td><td rowspan="1" colspan="1">28%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Trevisani et al[<xref rid="B4" ref-type="bibr">4</xref>]</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">16.50%</td><td rowspan="1" colspan="1">30%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Techathuvanan et al[<xref rid="B153" ref-type="bibr">153</xref>]</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">36%</td><td rowspan="1" colspan="1">34%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Chang et al[<xref rid="B154" ref-type="bibr">154</xref>]</td><td rowspan="1" colspan="1">98</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">44%</td><td rowspan="1" colspan="1">44.50%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Grazi et al[<xref rid="B155" ref-type="bibr">155</xref>]</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">21.50%</td><td rowspan="1" colspan="1">23%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Shim et al[<xref rid="B28" ref-type="bibr">28</xref>]</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">12.40%</td><td rowspan="1" colspan="1">4.10%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HBV</td><td rowspan="1" colspan="1">Nzeako et al[<xref rid="B52" ref-type="bibr">52</xref>]</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">5%</td><td rowspan="1" colspan="1">9.30%</td><td rowspan="1" colspan="1">30.60%</td><td rowspan="1" colspan="1">41.65%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Trevisani et al[<xref rid="B4" ref-type="bibr">4</xref>]</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">10%</td><td rowspan="1" colspan="1">22.55</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Techathuvanan et al[<xref rid="B153" ref-type="bibr">153</xref>]</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">10.60%</td><td rowspan="1" colspan="1">32%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Chang et al[<xref rid="B154" ref-type="bibr">154</xref>]</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">150</td><td rowspan="1" colspan="1">64.30%</td><td rowspan="1" colspan="1">69%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Grazi et al[<xref rid="B155" ref-type="bibr">155</xref>]</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">12.60%</td><td rowspan="1" colspan="1">14.90%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Shim et al[<xref rid="B28" ref-type="bibr">28</xref>]</td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">443</td><td rowspan="1" colspan="1">59%</td><td rowspan="1" colspan="1">83.30%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Kew et al[<xref rid="B156" ref-type="bibr">156</xref>]</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">52.80%</td><td rowspan="1" colspan="1">60.50%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HCV</td><td rowspan="1" colspan="1">Trevisani et al[<xref rid="B4" ref-type="bibr">4</xref>]</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">15%</td><td rowspan="1" colspan="1">76%</td><td rowspan="1" colspan="1">14.36%</td><td rowspan="1" colspan="1">44.18%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Chang et al[<xref rid="B154" ref-type="bibr">154</xref>]</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">18.10%</td><td rowspan="1" colspan="1">27.40%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Grazi et al[<xref rid="B155" ref-type="bibr">155</xref>]</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">182</td><td rowspan="1" colspan="1">24.40%</td><td rowspan="1" colspan="1">56.80%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Shim et al[<xref rid="B28" ref-type="bibr">28</xref>]</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">7.30%</td><td rowspan="1" colspan="1">5.10%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Albeldawi et al[<xref rid="B157" ref-type="bibr">157</xref>]</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">107</td><td rowspan="1" colspan="1">7%</td><td rowspan="1" colspan="1">55.70%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NASH</td><td rowspan="1" colspan="1">Sch&#x000fc;tte et al[<xref rid="B16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">6.45%</td><td rowspan="1" colspan="1">6.48%</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Cigarette smoking</td><td rowspan="1" colspan="1">Sch&#x000fc;tte et al[<xref rid="B16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">231</td><td rowspan="1" colspan="1">40%</td><td rowspan="1" colspan="1">47.60%</td><td rowspan="1" colspan="1">28.37%</td><td rowspan="1" colspan="1">32.10%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Trevisani et al[<xref rid="B4" ref-type="bibr">4</xref>]</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">20%</td><td rowspan="1" colspan="1">28%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Techathuvanan et al[<xref rid="B153" ref-type="bibr">153</xref>]</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">4.20%</td><td rowspan="1" colspan="1">2.80%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Chang et al[<xref rid="B154" ref-type="bibr">154</xref>]</td><td rowspan="1" colspan="1">110</td><td rowspan="1" colspan="1">111</td><td rowspan="1" colspan="1">49.30%</td><td rowspan="1" colspan="1">50%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes Mellitus</td><td rowspan="1" colspan="1">Sch&#x000fc;tte et al[<xref rid="B16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">368</td><td rowspan="1" colspan="1">71.20%</td><td rowspan="1" colspan="1">83.70%</td><td rowspan="1" colspan="1">40.73%</td><td rowspan="1" colspan="1">46.40%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Shim et al[<xref rid="B28" ref-type="bibr">28</xref>]</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">84</td><td rowspan="1" colspan="1">15.20%</td><td rowspan="1" colspan="1">15.80%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Albeldawi et al[<xref rid="B157" ref-type="bibr">157</xref>]</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">113</td><td rowspan="1" colspan="1">35.80%</td><td rowspan="1" colspan="1">39.70%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Family History</td><td rowspan="1" colspan="1">Techathuvanan et al[<xref rid="B153" ref-type="bibr">153</xref>]</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">12.30%</td><td rowspan="1" colspan="1">4.90%</td><td rowspan="1" colspan="1">13.85%</td><td rowspan="1" colspan="1">9.60%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Chang et al[<xref rid="B154" ref-type="bibr">154</xref>]</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">15.40%</td><td rowspan="1" colspan="1">14.30%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cryptogenic</td><td rowspan="1" colspan="1">Sch&#x000fc;tte et al[<xref rid="B16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">57%</td><td rowspan="1" colspan="1">11.38%</td><td rowspan="1" colspan="1">39.15%</td><td rowspan="1" colspan="1">9.44%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Shim et al[<xref rid="B28" ref-type="bibr">28</xref>]</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">21.30%</td><td rowspan="1" colspan="1">7.50%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Non-alcoholic steatohepatitis; NC: Non-cirrhotic liver; CL : Cirrhotic liver.</p></fn></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Causes of non-cirrhotic hepatocellular carcinoma. HCC: Hepatocellular carcinoma.</p></caption><graphic xlink:href="WJH-11-1-g001"/></fig><sec><title>Non-alcoholic fatty liver disease /Non-alcoholic steatohepatitis</title><p>Non-alcoholic fatty liver disease (NAFLD) comprises of a spectrum that includes isolated steatosis, non-alcoholic steatohepatitis <bold><italic>(</italic></bold>NASH, hepatic inflammation and cell death), fibrosis and cirrhosis (Table 1). With the growing obesity epidemic, NAFLD has become the most common liver disorder in the United States. A strong association has been reported between fatty liver disease and HCC in non-cirrhotic livers[<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>]. NAFLD-related HCC has been acknowledged as a growing burden in this country[<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>]. It has also been recognized as the most common etiology in new HCC cases, likely due to the recent advances in viral hepatitis, especially hepatitis C virus (HCV) treatment[<xref rid="B15" ref-type="bibr">15</xref>]. In a study performed by Sch&#x000fc;tte et al[<xref rid="B16" ref-type="bibr">16</xref>] the etiology of majority of HCC in non-cirrhotic liver was related to metabolic syndrome (MS). The causes of non-cirrhotic HCC is shown in Figure 1.</p><p>NAFLD, with or without NASH is the hepatic manifestation of MS and predisposes to HCC in non-cirrhotic patients[<xref rid="B17" ref-type="bibr">17</xref>]. Type 2 diabetes mellitus and obesity that is associated with NAFLD and MS leads to the release of multiple pro-inflammatory cytokines like TNF-alpha, IL-6, leptin and resistin and decreased amounts of adiponectin. These processes favor the development of hepatic steatosis and inflammation within the liver and subsequently precede the development of HCC[<xref rid="B12" ref-type="bibr">12</xref>]. Even though type 2 diabetes and obesity have both been implicated as independent risk factors for HCC, studies that establish a clear link to HCC in non-cirrhotic livers are scarce[<xref rid="B18" ref-type="bibr">18</xref>-<xref rid="B20" ref-type="bibr">20</xref>]. Not only MS and obesity but being overweight is also associated with higher risk of HCC. Overweight and obesity increase HCC prevalence in general population and especially in hepatitis B virus (HBV) and HCV patients[<xref rid="B21" ref-type="bibr">21</xref>]. Other features of MS like hypertension and dyslipidemia have not been extensively studied for the linkage. A recent Australian study comparing HCC characteristics between cirrhotic and non-cirrhotic NAFLD found that apart from the presence or absence of cirrhosis, the fibrosis stage was the only patient characteristic that conferred a worse prognosis as this was related to the size of the tumors (<italic>P</italic> = 0.03)[<xref rid="B22" ref-type="bibr">22</xref>].</p></sec><sec><title>Viral hepatitis</title><p>30% of HBV-related HCC occurs in non-cirrhotic patients[<xref rid="B23" ref-type="bibr">23</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). HBV, a partially double stranded DNA virus is able to integrate into the host cell and acts as a mutagenic agent causing secondary chromosomal rearrangement and increasing genomic instability. In addition, transactivation of genes by the regulatory protein HBx is known to increase cell proliferation, deregulate cell cycle control and interfere with DNA repair and apoptosis[<xref rid="B24" ref-type="bibr">24</xref>]. Certain risk factors in chronic hepatitis B patients in turn impart a higher risk for non-cirrhotic HCC. BCP T1762/A1764 mutation and high viral loads have been reported to be strong viral factors and independent predictors of HCC in non-cirrhotic patients who are chronic HBV carriers[<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>]. Older patients with chronic Hepatitis B had a higher annual incidence of non-cirrhotic HCC compared to cirrhotic patients; 1.1% per year in men and 0.3%-0.4% per year in women greater than the age of 55[<xref rid="B27" ref-type="bibr">27</xref>]. African American and Asian race has also been associated with a higher incidence of HCC in non-cirrhotic chronic hepatitis B patients[<xref rid="B27" ref-type="bibr">27</xref>]. About half of the cryptogenic HCC cases have occult Hepatitis B infection defined by the presence of HBV DNA in the liver or blood without HBsAg[<xref rid="B28" ref-type="bibr">28</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Computed tomography image of a 64-yr-old male with hepatitis B. No cirrhosis found to have large 9 cm mass in right lobe (arrows) on CT abdomen done for abdominal pain.</p></caption><graphic xlink:href="WJH-11-1-g002"/></fig><p>HCC in chronic Hepatitis C patients primarily occurs in the background of cirrhosis that is related to a necroinflammatory state with tissue damage, regeneration, repair and fibrosis[<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>]. HCV being a single stranded RNA virus cannot integrate with the host genome due to the absence of a DNA intermediate. However, it still possesses direct oncogenic potential although lower compared to HBV; with several of its gene products capable of contributing to carcinogenesis[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B31" ref-type="bibr">31</xref>]. The core protein can alter cell regulation <italic>via</italic> enhanced telomerase activity[<xref rid="B31" ref-type="bibr">31</xref>]. Non-structural proteins like NS3, NS4B and NS5A can potentially induce carcinogenesis through interactions with cellular promoters and proteins[<xref rid="B32" ref-type="bibr">32</xref>]. The incidence of HCC in non-cirrhotic HCV patients ranges from 4.4%-10.6%[<xref rid="B32" ref-type="bibr">32</xref>]. Its role as a major risk factor is suggested by the development of HCC even after eradication of the virus[<xref rid="B33" ref-type="bibr">33</xref>]. In treatment na&#x000ef;ve HCV patients, male gender, advanced age, persistently elevated aminotransferases, high gamma-glutamyl transferase levels, hepatic steatosis, diabetes and alcohol abuse have all been shown to increase the risk for non-cirrhotic HCC[<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>]. In patients with sustained virologic response after chronic HCV treatment, those who had diabetes mellitus and increased Fibrosis-4 index were at a higher risk. Studies have also shown increased risk of HCC in patients with hepatitis C and F3 fibrosis. Apart from hepatitis C, this increased risk is noted in even patients with hepatitis B and NAFLD who have F3 fibrosis[<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B36" ref-type="bibr">36</xref>]. The exact pathophysiology behind this still remains to be elucidated.</p></sec><sec><title>Genotoxic substances</title><p><bold>Alcohol:</bold> Several studies have shown heavy alcohol intake in patients with non-cirrhotic HCC, however most of these were not statistically significant[<xref rid="B4" ref-type="bibr">4</xref>]. Alcohol may not be a major cause in non-cirrhotic patients, but it should still be treated as a serious risk factor for the development of HCC. This is related to its direct genotoxic effect in the development of HCC mediated through endotoxin production, oxidative stress and inflammation[<xref rid="B37" ref-type="bibr">37</xref>]. Heavy alcohol intake in the setting of other risk factors like chronic HCV and diabetes mellitus may potentiate the oxidative stress and free radical damage; leading to rapid progression to HCC[<xref rid="B38" ref-type="bibr">38</xref>-<xref rid="B40" ref-type="bibr">40</xref>].</p><p><bold>Aflatoxin B1:</bold> Aflatoxin B1 (AFB1) is an extremely potent hepatocarcinogen that is a secondary metabolite produced by fungi, <italic>Aspergillus flavus</italic> and <italic>Aspergillus parasiticus</italic>. They are typically found in tropical and sub-tropical regions of the world in which grains such as rice stored in hot humid conditions promote growth of these toxin-producing fungi[<xref rid="B41" ref-type="bibr">41</xref>]. Most cases occur in sub-Saharan Africa, Southeast Asia and China where HBV is highly prevalent. However, its incidence in the United States is extremely low; 0.003 in HbsAg negative and 0.08 in HbsAg-positive patients[<xref rid="B42" ref-type="bibr">42</xref>]. In addition, its burden in non-cirrhotic individuals is unknown. AFB1 is metabolized by the P450 enzymes in the liver to generate an epoxide, which binds to DNA and induces mutation of the p53 tumor suppressor gene[<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B43" ref-type="bibr">43</xref>]. Like cirrhotic patients, non-cirrhotic patients with chronic HBV are also at a higher risk for aflatoxin-mediated HCC[<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>].</p><p><bold>Iron overload:</bold> Secondary iron overload is seen in patients with hematological disease like myelodysplastic syndrome, chronic anemia and polytransfusion[<xref rid="B46" ref-type="bibr">46</xref>-<xref rid="B48" ref-type="bibr">48</xref>]. The notion that increased liver iron stores in the liver cause HCC in non-cirrhotic patient has been present for at least three decades and there are several case reports that have highlighted the role of excess iron as a potential carcinogen[<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>]. Iron-induced carcinogenesis could be related to the production of reactive oxygen species <italic>via</italic> Fenton reaction inducing oxidative stress. This in turn promotes protein and DNA modification, blunts immune response by impairing T cell proliferation against tumor transformed cells and induces of p53 mutations[<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>].</p><p><bold>Miscellaneous:</bold> Chemical and industrial carcinogens like nitrosamines, azo dyes, aromatic amines, vinyl chloride, organic solvents, pesticides and arsenic have been known to induce carcinogenesis in non-cirrhotic liver[<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>]. Studies have shown KRAS mutations in vinyl chloride-induced HCC and HRAS mutations in methylene chloride-induced liver tumors[<xref rid="B23" ref-type="bibr">23</xref>]. Polycyclic aromatic hydrocarbons derived from red meat, cigarette smoking, and environmental pollutants also increase the risk of HCC by forming DNA adducts[<xref rid="B53" ref-type="bibr">53</xref>-<xref rid="B55" ref-type="bibr">55</xref>].</p><p><bold>Sex hormones:</bold> Several case reports have established a link between chronic anabolic androgen steroid abuse and non-cirrhotic HCC in young professional bodybuilders[<xref rid="B56" ref-type="bibr">56</xref>-<xref rid="B58" ref-type="bibr">58</xref>]. &#x0201c;Adenoma-carcinoma sequence&#x0201d; or &#x0201c;<italic>de novo</italic> carcinoma development&#x0201d; are the two proposed mechanisms for carcinogenesis[<xref rid="B56" ref-type="bibr">56</xref>]. Oral contraceptive (OCs) is also a known risk factor for the development of non-cirrhotic HCC[<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B60" ref-type="bibr">60</xref>]. In a retrospective case series of 26 white women aged under 50 who developed HCC in a non-cirrhotic liver, women who used OCs for 8 or more years had a 4.4-fold increased risk (<italic>P</italic> &#x0003c; 0.01)[<xref rid="B59" ref-type="bibr">59</xref>]. Both anabolic steroids and estrogen undergo significant enterohepatic circulation and slow biliary excretion, which increases intrahepatic concentrations and causes direct toxicity[<xref rid="B59" ref-type="bibr">59</xref>].</p></sec><sec><title>Inherited diseases</title><p>Hereditary hemochromatosis and alpha-1 antitrypsin deficiency are inherited diseases in which HCC occurs frequently without cirrhosis[<xref rid="B61" ref-type="bibr">61</xref>-<xref rid="B65" ref-type="bibr">65</xref>]. Acute hepatic porphyrias which include 3 autosomal dominant disorders: Acute intermittent porphyria (AIP), variegate porphyria (VP) and hereditary coproporphyria (HCP) has also been considered as a cause of non-cirrhotic HCC[<xref rid="B66" ref-type="bibr">66</xref>]. Overproduction of aminolevulinic acid and/or porphobilinogen overproduction and excretion has been implicated as a cause of hepatic carcinogenesis in AIP, but the mechanism is poorly understood in VP and HCP[<xref rid="B67" ref-type="bibr">67</xref>].</p><p>Hypercitrullinemia, a hereditary urea cycle disorder is associated with hepatocarcinogenesis in non-cirrhotic liver likely <italic>via</italic> citrulline-mediated promotion effect on hepatocyte proliferation[<xref rid="B68" ref-type="bibr">68</xref>].</p><p>Wilson&#x02019;s disease, an autosomal recessive disorder of copper metabolism is also implicated as cause of HCC in scattered case reports. The mechanism is related to copper mediated stimulation of fibroblast growth factor-2 and copper induced stabilization of hypoxia-inducible-factor-1 alpha, which causes expression of genes that promote angiogenesis[<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>]. Even though HCC prevalence in Wilson&#x02019;s disease is lower than other inherited forms of liver disease, it remains a significant risk factor for development of HCC in non-cirrhotic liver as well.</p><p>Glycogen storage disorders (GSD) are a group of inherited metabolic disorders characterized by the accumulation of excessive abnormal glycogen in liver, muscle or both. HCC typically occurs without cirrhosis in glycogen storage disease type 1 (GSD-1) <italic>via</italic> adenoma-carcinoma sequence[<xref rid="B62" ref-type="bibr">62</xref>]. HCC in GSD type III is extremely rare and generally occurs in the background of cirrhosis, however Oterdoom et al[<xref rid="B71" ref-type="bibr">71</xref>] reported the first documented case in a non-cirrhotic.</p><p>Alagille syndrome, an autosomal dominant disease that causes significant neonatal jaundice and cholestasis in older children has been shown in case reports to cause non-cirrhotic HCC[<xref rid="B72" ref-type="bibr">72</xref>,<xref rid="B73" ref-type="bibr">73</xref>].</p><p>Hepatic vascular disease like Budd-Chiari syndrome and nodular regenerative hyperplasia have been associated with non-cirrhotic HCC in case reports, however the mechanism of hepatocarcinogenesis in the absence of cirrhosis is unknown[<xref rid="B74" ref-type="bibr">74</xref>,<xref rid="B75" ref-type="bibr">75</xref>].</p></sec><sec><title>Germline mutations</title><p>Studies establishing associations between germline mutations and non-cirrhotic HCC have been scarce. In a recent study by Donati et al[<xref rid="B76" ref-type="bibr">76</xref>], germline mutations in telomerase reverse transcriptase gene (<italic>hTERT</italic>) were associated with shorter telomere lengths and progression of NAFLD to HCC in non-cirrhotic liver. Future studies may identify such germline mutations, which would allow for closer surveillance in these high-risk individuals.</p></sec><sec><title>Hepatic adenoma</title><p>Hepatic adenomas (HA) is a benign liver tumor that carries a small risk for the development of HCC[<xref rid="B60" ref-type="bibr">60</xref>]. The risk of malignant transformation is controversial and has been heavily debated based on available past research studies. Two studies that analyzed available literature, estimated this risk to be approximately 5%[<xref rid="B77" ref-type="bibr">77</xref>,<xref rid="B78" ref-type="bibr">78</xref>]. Studies on HA in non-cirrhotic livers have been scarce and those that exist have limitations related to overestimation of the risk and biased reviews of resected cases[<xref rid="B79" ref-type="bibr">79</xref>,<xref rid="B80" ref-type="bibr">80</xref>]. Nonetheless, there is compelling evidence in the literature to reserve resection of adenomas for adenoma diameter &#x0003e; 5 cm with telangiectatic or unclassified subtypes and male sex[<xref rid="B77" ref-type="bibr">77</xref>,<xref rid="B78" ref-type="bibr">78</xref>,<xref rid="B81" ref-type="bibr">81</xref>].</p></sec></sec><sec><title>CLINICAL FEATURES</title><p>HCC in non-cirrhotic patients is clinically silent in its early stages because of lack of symptoms and surveillance imaging; and higher hepatic reserve in this population[<xref rid="B82" ref-type="bibr">82</xref>]. The median age of these patients is 69 yr however, the FLC variant commonly occurs in adolescents and young adults, ranging from 10-35 yr at presentation[<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B16" ref-type="bibr">16</xref>]. Unfortunately, these tumors are often found in advanced stages with approximately 25% of non-cirrhotic HCC presenting with extra-hepatic metastasis[<xref rid="B16" ref-type="bibr">16</xref>]. When symptoms do occur, they arise due to large tumor burdens from its insidious progression. The most common presenting symptom is abdominal pain (52%). Other symptoms include abdominal distention, weight loss, malaise, anorexia, fatigue, chronic diarrhea, jaundice, chest pain and fever of unknown origin[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B83" ref-type="bibr">83</xref>,<xref rid="B84" ref-type="bibr">84</xref>]. Non-cirrhotic HCC can also present in the form of paraneoplastic syndrome of hypercalcemia or hypoglycemia[<xref rid="B82" ref-type="bibr">82</xref>,<xref rid="B85" ref-type="bibr">85</xref>]. FLC has been known to present with gynecomastia, recurrent deep vein thrombosis, Budd-Chiari syndrome, non-bacterial thrombotic endocarditis, fulminant liver failure or encephalopathy[<xref rid="B10" ref-type="bibr">10</xref>].</p></sec><sec><title>DIAGNOSIS</title><sec><title>Serum alpha-fetoprotein</title><p>Alpha-fetoprotein (AFP), a serum glycoprotein is a commonly used tumor marker for HCC[<xref rid="B86" ref-type="bibr">86</xref>]. Due to its poor sensitivity, the American Association for the Study of Liver Disease (AASLD) guidelines suggests surveillance with ultrasound with or without AFP in cirrhotic patients. In non-cirrhotic HCC, the sensitivity of AFP further decreases with elevation less common compared to cirrhotic HCC (31%-67% <italic>vs</italic> 63%-84%). AFP levels in majority of patients with the FLC-variant HCC are normal[<xref rid="B87" ref-type="bibr">87</xref>,<xref rid="B88" ref-type="bibr">88</xref>]. Levels &#x0003e; 400 ng/mL are essentially diagnostic for non-cirrhotic HCC and are equally prevalent in both groups[<xref rid="B89" ref-type="bibr">89</xref>]. This implies that elevated AFP levels may suggest a HCC, but normal levels should never be used to exclude the diagnosis, especially in a patient with high-risk factors. AFP levels however, may have a role in tumor surveillance and prognosis.</p></sec><sec><title>Des-gamma-carboxyprothrombin</title><p>Des-gamma-carboxyprothrombin (DCP) also known as PIVKA II (protein induced by vitamin K absence) is produced by malignant hepatocytes and its relationship to HCC has been known since 1984[<xref rid="B90" ref-type="bibr">90</xref>,<xref rid="B91" ref-type="bibr">91</xref>]. DCP has been reported to be more sensitive and specific than AFP for the diagnosis of HCC with a cutoff of &#x0003e; 40 mAU/mL[<xref rid="B92" ref-type="bibr">92</xref>]. However, its role in the detection of small tumors and early HCC is unclear as various studies have utilized different cutoff values for DCP and AFP[<xref rid="B92" ref-type="bibr">92</xref>-<xref rid="B94" ref-type="bibr">94</xref>]. Moreover, it has never been studied in non-cirrhotic patients. DCP might be the answer for early HCC diagnosis in non-cirrhotic patients along with monitoring treatment response and recurrence. Perhaps DCP could compliment AFP as evidenced by improved sensitivities emphasized in several studies[<xref rid="B91" ref-type="bibr">91</xref>,<xref rid="B93" ref-type="bibr">93</xref>]. Future studies should be directed towards establishing a relationship between elevated DCP and non-cirrhotic HCC.</p></sec><sec><title>Imaging</title><p>The radiological appearance of HCC in cirrhotic and non-cirrhotic patients is very similar, except HCC in non-cirrhotic livers frequently present as a solitary mass with or without satellite lesions, are much larger in tumor size and are often seen with a central scar[<xref rid="B95" ref-type="bibr">95</xref>].</p><p><bold>Ultrasonography</bold><italic>:</italic> Ultrasonography (US) is a non-invasive test that allows determining the size, location, morphology and vascular involvement of the lesion. The appearance of HCC on US is variable and non-specific ranging from hypo or hyperechoic lesions with or without heterogeneity or necrotic areas. This imaging modality is limited in the detection of tumors &#x0003c; 2 cm and tumors in a liver base with a heterogeneous diffuse nodular pattern[<xref rid="B82" ref-type="bibr">82</xref>,<xref rid="B84" ref-type="bibr">84</xref>].</p><p>Contrast-enhanced US (CEUS) could be valuable diagnostic tool because the dye allows its use in patients with nephropathies and those with known adverse reactions to other contrast agents[<xref rid="B82" ref-type="bibr">82</xref>]. CEUS shows a typical HCC vascular pattern, although inconsistently when compared to computed tomography (CT) and magnetic resonance imaging (MRI) especially for tumors &#x0003c; 2 cm[<xref rid="B96" ref-type="bibr">96</xref>-<xref rid="B99" ref-type="bibr">99</xref>]. There is a need for such studies in non-cirrhotic HCC, but for now its role in diagnosis is limited. However, it may have a role in guiding biopsies and monitoring tumor response to treatment with anti-angiogenic properties[<xref rid="B100" ref-type="bibr">100</xref>,<xref rid="B101" ref-type="bibr">101</xref>].</p><p><bold>Computed tomography</bold><italic>:</italic> CT scan can make the diagnosis of HCC with a high degree of confidence, hence proper technique and contrast administration is crucial for an accurate assessment (Figure <xref ref-type="fig" rid="F3">3</xref>)[<xref rid="B82" ref-type="bibr">82</xref>]. The main diagnostic criteria include hypervascularization on the arterial &#x0201c;wash-in&#x0201d; phase and washout during portal phase of enhancement, which is similar in cirrhotic and non-cirrhotic livers[<xref rid="B102" ref-type="bibr">102</xref>,<xref rid="B103" ref-type="bibr">103</xref>]. It often presents as a single large well-circumscribed encapsulated hypoattenuating lesion on unenhanced CT, with other tumor features like fat involvement, foci of hemorrhage and necrotic areas more common in non-cirrhotic HCC[<xref rid="B104" ref-type="bibr">104</xref>]. The FLC variant may show a similar pattern on contrast enhanced imaging as the classic non-cirrhotic HCC and often demonstrates internal calcifications, central scars and a discontinuous capsule[<xref rid="B105" ref-type="bibr">105</xref>].</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Computed tomography image of a 55-yr-old male with no significant past medical history found to have multifocal hepatocellular carcinoma in the right lobe of liver on imaging done for abdominal pain and jaundice.</p></caption><graphic xlink:href="WJH-11-1-g003"/></fig><p><bold>Magnetic resonance imaging:</bold> MRI is superior to CT for the diagnosis of HCC (Figure <xref ref-type="fig" rid="F4">4</xref>). Its appearance on T1 sequences varies depending on the degree of fibrosis, necrosis and fat but it more commonly presents as a hypointense lesion. Its appearance on T2 is variable as well but it is commonly a hyperintense lesion. Intracellular fat accumulation, which is present in 10%-17% of non-cirrhotic HCC and 36% of well-differentiated HCC is easier to detect on MRI compared to CT/US and signifies a better prognosis[<xref rid="B82" ref-type="bibr">82</xref>,<xref rid="B84" ref-type="bibr">84</xref>]. The gadolinium enhancement shows a similar pattern on MRI as described in contrast enhanced CT[<xref rid="B82" ref-type="bibr">82</xref>]. About 50% of non-cirrhotic HCC have a central scar that is detectable by MRI[<xref rid="B99" ref-type="bibr">99</xref>]. The FLC variant is hypointense on T1, hyperintense on T2 and heterogenous after gadolinium enhancement[<xref rid="B106" ref-type="bibr">106</xref>]. The central scar that is frequently seen in this subtype can be hypo or hyperintense on T2 sequences depending on the presence of necrosis and altered vascularity[<xref rid="B107" ref-type="bibr">107</xref>]. The differentiation between HCC and other benign liver lesions (focal nodular hyperplasia and hepatocellular adenoma) on MRI has been challenging in a non-cirrhotic liver often requiring unnecessary interventions for histopathological proof. In conclusion, T1 hypointensity, T2 hypo or hyperintensity, lack of central tumor enhancement and presence of satellite lesions are independent imaging factors, with a combined specificity of 98%, can allow MRI guided diagnosis of HCC in non-cirrhotic liver with a high level of confidence[<xref rid="B107" ref-type="bibr">107</xref>].</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Magnetic resonance imaging (e-THRIVE_BH AX 15 min delay) of 61-yr-old male with hepatitis C virus, without cirrhosis showing a 2.8 cm &#x000d7; 3 cm mass lesion in segment 5 consistent with hepatocellular carcinoma.</p></caption><graphic xlink:href="WJH-11-1-g004"/></fig></sec><sec><title>Percutaneous liver biopsy</title><p>Histological diagnosis <italic>via</italic> liver biopsy may only be necessary if imaging studies are inconclusive for being compatible with HCC[<xref rid="B108" ref-type="bibr">108</xref>-<xref rid="B110" ref-type="bibr">110</xref>]. The AASLD does not recommend biopsy for lesions &#x0003e; 1 cm if two different imaging studies yield concordant findings[<xref rid="B108" ref-type="bibr">108</xref>]. When performed, they are done <italic>via</italic> transabdominal technique under CT or US guidance with varying degrees of sensitivity (66%&#x02013;93% based on tumor size) and 100% specificity and positive predictive value[<xref rid="B109" ref-type="bibr">109</xref>]. Liver biopsy may be needed in patients who are not candidates for curative resection, to establish diagnosis for the purpose of systemic therapy or transplantation[<xref rid="B109" ref-type="bibr">109</xref>].</p></sec></sec><sec><title>MANAGEMENT</title><sec><title>Surgical Resection</title><p>Surgical resection is the treatment of choice for HCC in non-cirrhotic liver and is considered equally safe in non-cirrhotic and cirrhotic patients[<xref rid="B111" ref-type="bibr">111</xref>-<xref rid="B113" ref-type="bibr">113</xref>]. Since clinical staging systems like Okuda/Barcelona-Clinic Liver Cancer associated with underlying cirrhosis are not relevant in these patients, primary tumor features are utilized for staging and prognosis. Patients that are typically not candidates for surgical resection are those that have extrahepatic spread of their disease or anatomical constraints related to the tumor. Majority of the patients require a major hepatic resection, often with advanced surgical techniques for inferior vena cava or diaphragmatic resection; or total vascular exclusion[<xref rid="B114" ref-type="bibr">114</xref>]. These surgeries are feasible due to the preserved liver function and low perioperative mortality when compared to cirrhotic livers[<xref rid="B114" ref-type="bibr">114</xref>]. Common complications associated with such resections include intra-abdominal collections and liver insufficiency[<xref rid="B115" ref-type="bibr">115</xref>]. Perioperative morbidity and mortality is low when compared to the cirrhotic liver, 29.5% and 2.7% respectively[<xref rid="B115" ref-type="bibr">115</xref>]. Impressive postoperative survival rates of 96%, 87% and 68% after 1, 3 and 5-yr respectively have been reported in patients with tumors without vascular invasion; factors such as portal vein thrombosis, lymph node involvement and tumor recurrence are associated with poor outcomes[<xref rid="B112" ref-type="bibr">112</xref>,<xref rid="B113" ref-type="bibr">113</xref>].</p></sec><sec><title>Tumor recurrence</title><p>Tumor recurrence is the major cause of death in non-cirrhotic livers with HCC since no effective post-operative adjuvant chemotherapy exists[<xref rid="B116" ref-type="bibr">116</xref>,<xref rid="B117" ref-type="bibr">117</xref>]. The recurrence rate of HCC in non-cirrhotic liver is extremely high after surgical resection. Taking into account the best reported figures, the 1, 3 and 5-yr disease free survival rate is 79%, 58% and 54% respectively. Repeat hepatectomy is feasible in these patients due to normal liver function, which allows for good regenerative capacity. A mean time recurrence of 31 mo with a 61% 5-yr survival and 25% 10-yr survival after a first repeat hepatectomy has been reported for non-cirrhotic patients[<xref rid="B116" ref-type="bibr">116</xref>]. A good functioning liver also allows for repeat second and third hepatectomies in these patients and can be considered equally safe and effective when compared to the first[<xref rid="B84" ref-type="bibr">84</xref>]. However, when surgical resections fail to control recurrent disease or repeat tumors are considered unresectable, patients may need to be evaluated for liver transplantation (LT).</p></sec><sec><title>LT</title><p>Historically, LT was not routinely recommended in non-cirrhotic HCC due to the lack of precise guidelines or selection criteria for this patient population. Very early reports and studies have demonstrated high tumor recurrences and dismal survival outcomes. A systematic review of all reported cases of LT in non-cirrhotic patients from 1966-1988 reported a 5-yr survival rate of 11.2% for HCC and 39.4% for the FLC variant[<xref rid="B118" ref-type="bibr">118</xref>]. McPeake et al[<xref rid="B119" ref-type="bibr">119</xref>] reported a 40% recurrence rate for lesions 4-8 cm and 78% in lesions &#x0003e; 8 cm. However, Mergental et al[<xref rid="B120" ref-type="bibr">120</xref>] reported a 5-yr survival of 50%-70% after analysis of literature and European Liver Transplant Registry with median tumor sizes of 8 cm. This study recommends that Milan criteria should not be used to exclude patients with non-cirrhotic HCC and identified extrahepatic spread, gross vascular or lymph node involvement, multiple tumors and tumor recurrence &#x0003c; 1 yr after resection as predictors of poor outcome after LT. Based on these findings, an international consensus conference report recommended LT in patients with non-resectable HCC or in patients who experience intrahepatic recurrence after surgical resection; provided these patients have no macrovascular invasion or extrahepatic spread[<xref rid="B121" ref-type="bibr">121</xref>]. Decaens et al[<xref rid="B122" ref-type="bibr">122</xref>] highlighted the need for prospective studies addressing pre-LT imaging for tumor characteristics, response to treatment performed and kinetics of tumor progression during the waiting period and rate of dropout from tumor progression. It will be interesting to note the recurrence and overall survival (OS) of these patients in future studies after improved patient selection and advances in perioperative management and surgical care.</p></sec><sec><title>Systemic therapy</title><p>Sorafenib is an Food and Drug Administration (FDA) approved oral multi-tyrosine kinase inhibitor, which is the first line therapy for patients with advanced HCC[<xref rid="B123" ref-type="bibr">123</xref>,<xref rid="B124" ref-type="bibr">124</xref>]. It is indicated in patients who are not deemed surgical or transplant candidates with preserved liver function. It inhibits tumor growth and has anti-proliferative, anti-angiogenic and pro-apoptotic features[<xref rid="B125" ref-type="bibr">125</xref>]. The most common side effects reported include diarrhea and hand-foot skin reactions[<xref rid="B126" ref-type="bibr">126</xref>]. Sorafenib has demonstrated survival benefit in cirrhotic HCC, however no studies have formally evaluated outcomes in patients with a non-cirrhotic liver. Given the similarity of angiogenic characteristics between cirrhotic and non-cirrhotic HCC, Sorafenib could have a role in the management of advanced HCC in non-cirrhotic patients[<xref rid="B127" ref-type="bibr">127</xref>]. Recently, the FDA approved two new systemic drugs for advanced HCC. Regorafenib, a multikinase inhibitor, and Nivolumab, a PD-1 (programmed cell death protein 1) inhibitor have shown survival benefit in patients who had disease progression despite treatment with Sorafenib[<xref rid="B128" ref-type="bibr">128</xref>,<xref rid="B129" ref-type="bibr">129</xref>].</p><p>Systemic chemotherapy with other agents has been ineffective and has resulted in sub-optimal outcomes in cirrhotic advanced HCC. This has been largely due to the underlying cirrhosis with altered drug metabolism, which can lead to serious toxicity requiring either decrease in the dose or discontinuation[<xref rid="B130" ref-type="bibr">130</xref>,<xref rid="B131" ref-type="bibr">131</xref>]. However, non-cirrhotic HCC patients with a healthy liver may be able to tolerate these agents. Edeline et al[<xref rid="B132" ref-type="bibr">132</xref>] in their study had a 52% disease control rate with ECC (epirubicin, cisplatin and 5-flurouracil) or ECF (epirubicin, cisplastin and capecitabine). Romano et al[<xref rid="B130" ref-type="bibr">130</xref>] demonstrated partial response to Docetaxel with long-term survival and without severe toxicity in 3 patients. Gras et al[<xref rid="B133" ref-type="bibr">133</xref>] reported a complete response with GEMOX chemotherapy without a 5-yr relapse after discontinuation in a patient with advanced FLC-HCC in a non-cirrhotic liver. These reports highlight the need for further trials to explore the use of systemic chemotherapy to improve prognosis of patients with advanced non-cirrhotic HCC. Systemic chemotherapy may result in downsizing of the tumor allowing such patients to be candidates for curative surgical resection or liver transplant.</p><p>There have been few studies that have evaluated the combination of Sorafenib with other systemic chemotherapeutic agents in non-cirrhotic advanced HCC. In patients who experience recurrences after LT, combination of Sorafenib and mTOR inhibitor in conjunction with locoregional treatments improved survival, with 1 and 5-year survival rates of 82% and 33% respectively[<xref rid="B134" ref-type="bibr">134</xref>]. This could open potential avenues for research for combination chemotherapy and loco-ablative techniques like radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and radio-embolization commonly employed in cirrhotic HCC; in the management of non-cirrhotic HCC.</p></sec><sec><title>Loco-ablative therapies and selective internal radiation therapy</title><p>Local ablation therapies like RFA and TACE are considered first line treatment options for unresectable HCC in cirrhotic patients. These techniques along with selective internal radiation therapy (SIRT) have been employed for down staging of tumors and control progression[<xref rid="B135" ref-type="bibr">135</xref>,<xref rid="B136" ref-type="bibr">136</xref>]. Unfortunately, their role in non-cirrhotic HCC has not been established in studies likely due to the rarity of the disease, benefit of other treatment modalities, poor prognosis and high tumor recurrence. However, for metastatic disease after prior hepatectomy, RFA has been associated with improved progression free survival and OS when compared to transcatheter therapy[<xref rid="B135" ref-type="bibr">135</xref>].</p><p>A recent case report published by Mafeld et al[<xref rid="B136" ref-type="bibr">136</xref>] showed a 94% reduction in tumor size 7 mo after SIRT with Yttrium-90 for unresectable FLC-HCC after which the patient underwent a curative surgical resection. Studies establishing SIRT as a standard of care in regular non-cirrhotic HCC may be difficult given its high 90-d morbidity; complications and lack of long term follow up data in the current case[<xref rid="B136" ref-type="bibr">136</xref>]. However, SIRT should be considered for the FLC-variant given limited treatment options for unresectable disease and its grave prognosis.</p></sec></sec><sec><title>PROGNOSIS AND SURVEILLANCE</title><p>Survival of patients with HCC in non-cirrhotic liver mainly depends on tumor related factors such as tumor size, existence of satellite lesions, lack of tumor capsule, vascular invasion, grading, incomplete resection, HBV infection and the amount of intraoperative blood transfusions[<xref rid="B117" ref-type="bibr">117</xref>,<xref rid="B137" ref-type="bibr">137</xref>-<xref rid="B139" ref-type="bibr">139</xref>]. Poor prognostic factors that affected the OS rate in patients undergoing surgical resection include the need for blood transfusion and advanced age &#x0003e; 65. Factors that affected the recurrence free survival rate included the presence of multiple tumors[<xref rid="B117" ref-type="bibr">117</xref>]. FLC-HCC has a 70% 5-yr survival following surgical resection whereas for unresectable disease, the 5-yr survival rate is 0-5% with a median survival of 12 mo[<xref rid="B140" ref-type="bibr">140</xref>]. The number of tumors and vascular invasion are considered poor prognostic factors in this variant; the 3-yr recurrence free survival rate is 9% in patients with vascular invasion and 35% without[<xref rid="B140" ref-type="bibr">140</xref>].</p><p>AFP levels could be better suited as prognostic indicators. Burnett et al[<xref rid="B141" ref-type="bibr">141</xref>] used AFP staging based on four levels: &#x0003c; 10 ng/mL, 10 to 150 ng/mL, 150 to 500 ng/mL and &#x0003e; 500 ng/mL; and found these to be appropriate predictors of prognosis in non-cirrhotic HCC. Witjes et al[<xref rid="B89" ref-type="bibr">89</xref>] showed that elevated pre-operative AFP levels were associated with worse outcomes and high recurrence rates. Using an AFP cut off of 9 ng/mL, they demonstrated 1 and 3-yr survival rates of 53% and 21% respectively in patients with high AFP and 86% and 75% in patients with low AFP.</p><p>The need for effective surveillance needs to be addressed given the high tumor recurrence rate. The most common and significant issue raised is the delayed presentation of HCC in non-cirrhotic patients. There is a further need to direct research towards alternative cost-effective surveillance strategies and risk factor profiling to identify this high-risk population, decrease the tumor burden upon presentation and improve survival outcomes. Fu et al. reported a high association between high relative telomere length (RTL) and risk of HCC in non-cirrhotic chronic hepatitis B patients. Future studies could expand the role of RTL in serum DNA as a non-invasive biomarker for surveillance in non-cirrhotic HCC[<xref rid="B142" ref-type="bibr">142</xref>]. Wang et al[<xref rid="B143" ref-type="bibr">143</xref>] developed a prognostic scoring system of HCC after hepatectomy based on 11 independent risk factors and classified patients into low, intermediate and high-risk groups with an 80, 27 and 6-mo recurrence free survival respectively in each group. Such categorization is perhaps what is required in non-cirrhotic patients. Alkaline phosphatase (ALP) has also been reported as an independent risk factor that affects recurrence-free and survival rates[<xref rid="B139" ref-type="bibr">139</xref>]. High ALP levels could have a potential role in predicting HCC recurrence in non-cirrhotic patients and could be part of guidelines that establish risk for tumor recurrence. Further studies are necessary however, to validate the use of such scoring systems. This might allow for a more cost-effective and economic surveillance in high and intermediate risk groups.</p></sec><sec><title>FUTURE CONSIDERATIONS</title><sec><title>microRNA</title><p>microRNAs (miRNAs) are endogenous non-coding 21-23 nucleotide RNAs that are involved in post-transcriptional regulation and thus play an important role in almost all main cellular pathways including regulation of major tumor-related genes in carcinogenesis[<xref rid="B144" ref-type="bibr">144</xref>,<xref rid="B145" ref-type="bibr">145</xref>]. miRNAs are also involved in iron metabolism through regulation of genes that control iron homeostasis in hepatocytes[<xref rid="B146" ref-type="bibr">146</xref>]. Dysregulation of miRNAs can lead to iron overload which can lead to the generation of reactive oxygen species and cause oxidative stress which damages DNA, lipids and proteins[<xref rid="B147" ref-type="bibr">147</xref>]. miRNA could serve as important diagnostic and prognostic biomarkers in non-cirrhotic HCC. Koh et al[<xref rid="B148" ref-type="bibr">148</xref>] identified 16 miRNAs that displayed significant change in expression non-tumor and HCC tissues in non-cirrhotic livers. Analysis of miRNA in the serum is an exciting prospect for the diagnosis and/or prognosis of non-cirrhotic HCC.</p><p>Early and unique changes in circulating miRNA in the serum could potentially allow it to be a biomarker for the early detection of non-cirrhotic HCC. In a study performed by Zhang et al[<xref rid="B149" ref-type="bibr">149</xref>], a 3 mi-RNA panel comprising of miR-92-3p, miR-107, and miR-3126-5p was equally effective as AFP for diagnosis of early HCC. Furthermore, the combination of miRNA panel and AFP had higher sensitivity and specificity than AFP alone, especially in patients with early HCC or low-level AFP. However, the study did not specify presence or absence of cirrhosis in the patient cohort. miRNA could also serve as an important prognostic marker in non-cirrhotic liver. Dysregulation of certain miRNA has been associated with poor disease-free survival after liver resection of HCC[<xref rid="B145" ref-type="bibr">145</xref>]. Another study showed low levels of miRNA (miR-181a-5p) and poor disease control after Sorafenib therapy[<xref rid="B150" ref-type="bibr">150</xref>]. Again, these studies did not comment on background liver cirrhosis. In a recent study by Mei et al[<xref rid="B151" ref-type="bibr">151</xref>] cirrhotic and non-cirrhotic HCC patients were found to have 41 differentially expressed miRNAs. Specifically, two miRNAs (mir-149 and mir-1296) were strongly associated with non-cirrhotic HCC and influenced the TMN tumor staging. Furthermore, increased mir-149 was associated with increased post-operative survival in non-cirrhotic HCC. Huang et al[<xref rid="B152" ref-type="bibr">152</xref>] developed 5-panel mi-RNA that capable of assessing risk in HCC patients. The hope is that future studies could identify a similar miRNA signature for non-cirrhotic HCC patients. Hence, miRNAs are an exciting future research prospect and could perhaps be the solution for improved diagnosis, surveillance and prognosis along with therapeutic management of advanced non-cirrhotic HCC.</p></sec></sec><sec><title>CONTRIBUTIONS</title><p>The current review should help make significant contributions to research progress for HCC in non-cirrhotic liver. It highlights the major risk factors implicated in the development of HCC in a non-cirrhotic liver; especially NAFLD/NASH. It also brings to attention other rare risk factors that would further assist clinicians in decreasing the incidence of cryptogenic HCC. The review has also attempted to drive research towards finding alternative means of diagnosing non-cirrhotic HCC early by exploring other tumor markers like DCP as well as improve surveillance and monitoring of these patients. Finally, the review placed special emphasis on the management of non-cirrhotic HCC by incorporating the latest literature, which would allow researcher to explore other potential avenues especially systematic chemotherapy and loco-ablative techniques.</p></sec><sec><title>CONCLUSION</title><p>HCC in a non-cirrhotic liver is a complex disease phenomenon with risk factors, pathogenesis, clinical features, management and prognosis that are distinct from the cirrhotic counterpart. Even though considerable progress has been made in the management of this entity, there is a dire need for implementation of surveillance strategies in the patient population at risk, to decrease the disease burden at presentation and improve the prognosis of these patients. The hope is that this review sparks further research to close the knowledge gap and uncover answers to questions that have puzzled experts for decades.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Conflict-of-interest statement: No potential conflicts of interest.</p></fn><fn><p>Manuscript source: Unsolicited manuscript</p></fn><fn><p>Peer-review started: August 24, 2018</p></fn><fn><p>First decision: October 4, 2018</p></fn><fn><p>Article in press: December 31, 2018</p></fn><fn><p>Specialty type: Gastroenterology and hepatology</p></fn><fn><p>Country of origin: United States</p></fn><fn><p>Peer-review report classification</p></fn><fn><p>Grade A (Excellent): 0</p></fn><fn><p>Grade B (Very good): B, B</p></fn><fn><p>Grade C (Good): C, C, C, C</p></fn><fn><p>Grade D (Fair): 0</p></fn><fn><p>Grade E (Poor): 0</p></fn><fn><p>P- Reviewer: Gencdal G, Jarcuska P, Luo GH, Quarleri J, Sirin G, Zhu YY S- Editor: Yan JP L- Editor: A E- Editor: Tan WW</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananthakrishnan</surname><given-names>A</given-names></name><name><surname>Gogineni</surname><given-names>V</given-names></name><name><surname>Saeian</surname><given-names>K</given-names></name></person-group><article-title>Epidemiology of primary and secondary liver cancers</article-title><source>Semin Intervent Radiol</source><year>2006</year><volume>23</volume><fpage>47</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21326720</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><year>2005</year><volume>55</volume><fpage>74</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Dikshit</surname><given-names>R</given-names></name><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Rebelo</surname><given-names>M</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><fpage>E359</fpage><lpage>E386</lpage><pub-id pub-id-type="pmid">25220842</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trevisani</surname><given-names>F</given-names></name><name><surname>Frigerio</surname><given-names>M</given-names></name><name><surname>Santi</surname><given-names>V</given-names></name><name><surname>Grignaschi</surname><given-names>A</given-names></name><name><surname>Bernardi</surname><given-names>M</given-names></name></person-group><article-title>Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal</article-title><source>Dig Liver Dis</source><year>2010</year><volume>42</volume><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">19828388</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name></person-group><article-title>Primary malignant tumours in the non-cirrhotic liver</article-title><source>Eur J Radiol</source><year>2017</year><volume>95</volume><fpage>349</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">28987692</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>KW</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Qiao</surname><given-names>L</given-names></name></person-group><article-title>Fibrolamellar hepatocellular carcinoma</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>2617</fpage><lpage>24; quiz 2625</lpage><pub-id pub-id-type="pmid">19638962</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stipa</surname><given-names>F</given-names></name><name><surname>Yoon</surname><given-names>SS</given-names></name><name><surname>Liau</surname><given-names>KH</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>D&#x02019;Angelica</surname><given-names>M</given-names></name><name><surname>Abou-Alfa</surname><given-names>G</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name></person-group><article-title>Outcome of patients with fibrolamellar hepatocellular carcinoma</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>1331</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">16475212</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name></person-group><article-title>Epidemiology of hepatocellular carcinoma: consider the population</article-title><source>J Clin Gastroenterol</source><year>2013</year><volume>47 Suppl</volume><fpage>S2</fpage><lpage>S6</lpage><pub-id pub-id-type="pmid">23632345</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2018</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">29313949</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganeshan</surname><given-names>D</given-names></name><name><surname>Szklaruk</surname><given-names>J</given-names></name><name><surname>Kundra</surname><given-names>V</given-names></name><name><surname>Kaseb</surname><given-names>A</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name><name><surname>Elsayes</surname><given-names>KM</given-names></name></person-group><article-title>Imaging features of fibrolamellar hepatocellular carcinoma</article-title><source>AJR Am J Roentgenol</source><year>2014</year><volume>202</volume><fpage>544</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">24555590</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafaro</surname><given-names>KJ</given-names></name><name><surname>Pawlik</surname><given-names>TM</given-names></name></person-group><article-title>Fibrolamellar hepatocellular carcinoma: current clinical perspectives</article-title><source>J Hepatocell Carcinoma</source><year>2015</year><volume>2</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">27508204</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perumpail</surname><given-names>RB</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>SA</given-names></name></person-group><article-title>Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways</article-title><source>World J Hepatol</source><year>2015</year><volume>7</volume><fpage>2384</fpage><lpage>2388</lpage><pub-id pub-id-type="pmid">26464753</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pi&#x000f1;ero</surname><given-names>F</given-names></name><name><surname>Pages</surname><given-names>J</given-names></name><name><surname>Marciano</surname><given-names>S</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>N</given-names></name><name><surname>Silva</surname><given-names>J</given-names></name><name><surname>Anders</surname><given-names>M</given-names></name><name><surname>Zerega</surname><given-names>A</given-names></name><name><surname>Ridruejo</surname><given-names>E</given-names></name><name><surname>Ameigeiras</surname><given-names>B</given-names></name><name><surname>D'Amico</surname><given-names>C</given-names></name><name><surname>Gaite</surname><given-names>L</given-names></name><name><surname>Berm&#x000fa;dez</surname><given-names>C</given-names></name><name><surname>Cobos</surname><given-names>M</given-names></name><name><surname>Rosales</surname><given-names>C</given-names></name><name><surname>Romero</surname><given-names>G</given-names></name><name><surname>McCormack</surname><given-names>L</given-names></name><name><surname>Reggiardo</surname><given-names>V</given-names></name><name><surname>Colombato</surname><given-names>L</given-names></name><name><surname>Gadano</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name></person-group><article-title>Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina</article-title><source>World J Hepatol</source><year>2018</year><volume>10</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">29399277</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>J</given-names></name><name><surname>Torbenson</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>TT</given-names></name><name><surname>Yeh</surname><given-names>MM</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study</article-title><source>J Gastroenterol Hepatol</source><year>2013</year><volume>28</volume><fpage>848</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">23302015</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margini</surname><given-names>C</given-names></name><name><surname>Dufour</surname><given-names>JF</given-names></name></person-group><article-title>The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment</article-title><source>Liver Int</source><year>2016</year><volume>36</volume><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">26601627</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;tte</surname><given-names>K</given-names></name><name><surname>Schulz</surname><given-names>C</given-names></name><name><surname>Poranzke</surname><given-names>J</given-names></name><name><surname>Antweiler</surname><given-names>K</given-names></name><name><surname>Bornschein</surname><given-names>J</given-names></name><name><surname>Bretschneider</surname><given-names>T</given-names></name><name><surname>Arend</surname><given-names>J</given-names></name><name><surname>Ricke</surname><given-names>J</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name></person-group><article-title>Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver</article-title><source>BMC Gastroenterol</source><year>2014</year><volume>14</volume><fpage>117</fpage><pub-id pub-id-type="pmid">24990270</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balakrishnan</surname><given-names>M</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name></person-group><article-title>Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis?</article-title><source>Aliment Pharmacol Ther</source><year>2018</year><volume>47</volume><fpage>437</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">29314126</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davila</surname><given-names>JA</given-names></name><name><surname>Morgan</surname><given-names>RO</given-names></name><name><surname>Shaib</surname><given-names>Y</given-names></name><name><surname>McGlynn</surname><given-names>KA</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name></person-group><article-title>Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">15753540</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dongiovanni</surname><given-names>P</given-names></name><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Valenti</surname><given-names>L</given-names></name></person-group><article-title>Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>12945</fpage><lpage>12955</lpage><pub-id pub-id-type="pmid">25278690</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name></person-group><article-title>Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies</article-title><source>Br J Cancer</source><year>2007</year><volume>97</volume><fpage>1005</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">17700568</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>R</given-names></name><name><surname>Hammoud</surname><given-names>GM</given-names></name><name><surname>Almashhrawi</surname><given-names>AA</given-names></name><name><surname>Ahmed</surname><given-names>KT</given-names></name><name><surname>Ibdah</surname><given-names>JA</given-names></name></person-group><article-title>Primary hepatocellular carcinoma and metabolic syndrome: An update</article-title><source>World J Gastrointest Oncol</source><year>2013</year><volume>5</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">24069511</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>C</given-names></name><name><surname>Yeoh</surname><given-names>SW</given-names></name><name><surname>Patrick</surname><given-names>D</given-names></name><name><surname>Ket</surname><given-names>S</given-names></name><name><surname>Marion</surname><given-names>K</given-names></name><name><surname>Gow</surname><given-names>P</given-names></name><name><surname>Angus</surname><given-names>PW</given-names></name></person-group><article-title>Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><fpage>1189</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">25632192</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Yoon</surname><given-names>SK</given-names></name><name><surname>Lencioni</surname><given-names>R</given-names></name></person-group><article-title>The etiology of hepatocellular carcinoma and consequences for treatment</article-title><source>Oncologist</source><year>2010</year><volume>15 Suppl 4</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">21115577</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>BF</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Lai</surname><given-names>MY</given-names></name><name><surname>Huang</surname><given-names>WL</given-names></name><name><surname>Kao</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name></person-group><article-title>Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study</article-title><source>J Infect Dis</source><year>2006</year><volume>194</volume><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">16897657</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>AL</given-names></name><name><surname>Wong</surname><given-names>CR</given-names></name><name><surname>Nguyen</surname><given-names>LH</given-names></name><name><surname>Nguyen</surname><given-names>VG</given-names></name><name><surname>Trinh</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>MH</given-names></name></person-group><article-title>Hepatocellular carcinoma incidence in noncirrhotic patients with chronic hepatitis B and patients with cirrhosis of all etiologies</article-title><source>J Clin Gastroenterol</source><year>2014</year><volume>48</volume><fpage>644</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">24201999</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Lai</surname><given-names>MY</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name></person-group><article-title>Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers</article-title><source>Gastroenterology</source><year>2003</year><volume>124</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">12557138</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chayanupatkul</surname><given-names>M</given-names></name><name><surname>Omino</surname><given-names>R</given-names></name><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>Kramer</surname><given-names>JR</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Kanwal</surname><given-names>F</given-names></name></person-group><article-title>12 The Risk Factors of Hepatocellular Carcinoma (HCC) in Non-Cirrhotic Chronic Hepatitis B Patients in United States Veterans</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><fpage>S4</fpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>CW</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>BH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Hong</surname><given-names>EK</given-names></name></person-group><article-title>Noncirrhotic hepatocellular carcinoma: Etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area</article-title><source>Therap Adv Gastroenterol</source><year>2017</year><volume>10</volume><fpage>529</fpage><lpage>536</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><collab>el-Refaie A, Savage K, Bhattacharya S, Khakoo S, Harrison TJ, el-Batanony M, Soliman el-S, Nasr S, Mokhtar N, Amer K, Scheuer PJ, Dhillon AP</collab><article-title>HCV-associated hepatocellular carcinoma without cirrhosis</article-title><source>J Hepatol</source><year>1996</year><volume>24</volume><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">8778193</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>KL</given-names></name><name><surname>Woodall</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>AS</given-names></name><name><surname>Davies</surname><given-names>SE</given-names></name><name><surname>Alexander</surname><given-names>GJ</given-names></name></person-group><article-title>Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>4061</fpage><lpage>4065</lpage><pub-id pub-id-type="pmid">20731020</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>RB</given-names></name><name><surname>Meyer</surname><given-names>K</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name></person-group><article-title>Hepatitis C virus core protein promotes immortalization of primary human hepatocytes</article-title><source>Virology</source><year>2000</year><volume>271</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">10814584</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alotaibi</surname><given-names>AS</given-names></name><name><surname>Alghamdi</surname><given-names>W</given-names></name><name><surname>Marotta</surname><given-names>P</given-names></name><name><surname>Qumosani</surname><given-names>K</given-names></name></person-group><article-title>A266 Hepatocellular Carcinoma Prevalence In Non-Cirrhotic Hepatitis C Patients. J</article-title><source>Can Assoc Gastroenterol</source><year>2018</year><volume>1</volume><fpage>383</fpage><lpage>384</lpage></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattos</surname><given-names>AA</given-names></name><name><surname>Marcon Pdos</surname><given-names>S</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>FS</given-names></name><name><surname>Coral</surname><given-names>GP</given-names></name><name><surname>Tovo</surname><given-names>CV</given-names></name></person-group><article-title>Hepatocellular carcinoma in a non-cirrhotic patient with sustained virological response after hepatitis c treatment</article-title><source>Rev Inst Med Trop Sao Paulo</source><year>2015</year><volume>57</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">27049708</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>E</given-names></name><name><surname>Bassi</surname><given-names>F</given-names></name><name><surname>Fornaciari</surname><given-names>G</given-names></name></person-group><article-title>Deveopment of hepatocellular carcinoma in a non-cirrhotic, long-term responder to antiviral therapy, chronic hepatitis C patient: what kind of surveillance?</article-title><source>Ann Gastroenterol</source><year>2013</year><volume>26</volume><fpage>80</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">24714548</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CF</given-names></name><name><surname>Yeh</surname><given-names>ML</given-names></name><name><surname>Tsai</surname><given-names>PC</given-names></name><name><surname>Hsieh</surname><given-names>MH</given-names></name><name><surname>Yang</surname><given-names>HL</given-names></name><name><surname>Hsieh</surname><given-names>MY</given-names></name><name><surname>Yang</surname><given-names>JF</given-names></name><name><surname>Lin</surname><given-names>ZY</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Dai</surname><given-names>CY</given-names></name><name><surname>Huang</surname><given-names>JF</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><name><surname>Yu</surname><given-names>ML</given-names></name></person-group><article-title>Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">24613362</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyoda</surname><given-names>H</given-names></name><name><surname>Kumada</surname><given-names>T</given-names></name><name><surname>Tada</surname><given-names>T</given-names></name><name><surname>Kiriyama</surname><given-names>S</given-names></name><name><surname>Tanikawa</surname><given-names>M</given-names></name><name><surname>Hisanaga</surname><given-names>Y</given-names></name><name><surname>Kanamori</surname><given-names>A</given-names></name><name><surname>Kitabatake</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name></person-group><article-title>Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection</article-title><source>J Gastroenterol Hepatol</source><year>2015</year><volume>30</volume><fpage>1183</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">25678094</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testino</surname><given-names>G</given-names></name><name><surname>Leone</surname><given-names>S</given-names></name><name><surname>Borro</surname><given-names>P</given-names></name></person-group><article-title>Alcohol and hepatocellular carcinoma: a review and a point of view</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>15943</fpage><lpage>15954</lpage><pub-id pub-id-type="pmid">25473148</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>MM</given-names></name><name><surname>Hwang</surname><given-names>LY</given-names></name><name><surname>Hatten</surname><given-names>CJ</given-names></name><name><surname>Swaim</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Beasley</surname><given-names>P</given-names></name><name><surname>Patt</surname><given-names>YZ</given-names></name></person-group><article-title>Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus</article-title><source>Hepatology</source><year>2002</year><volume>36</volume><fpage>1206</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">12395331</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safdar</surname><given-names>K</given-names></name><name><surname>Schiff</surname><given-names>ER</given-names></name></person-group><article-title>Alcohol and hepatitis C</article-title><source>Semin Liver Dis</source><year>2004</year><volume>24</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">15349807</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>JM</given-names></name><name><surname>Govindarajan</surname><given-names>S</given-names></name><name><surname>Arakawa</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name></person-group><article-title>Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S</article-title><source>Cancer</source><year>2004</year><volume>101</volume><fpage>1009</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">15329910</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugavel</surname><given-names>KG</given-names></name><name><surname>Naranatt</surname><given-names>PP</given-names></name><name><surname>Shankar</surname><given-names>EM</given-names></name><name><surname>Mathews</surname><given-names>S</given-names></name><name><surname>Raghuram</surname><given-names>K</given-names></name><name><surname>Rajasambandam</surname><given-names>P</given-names></name><name><surname>Jayanthi</surname><given-names>V</given-names></name><name><surname>Surendran</surname><given-names>R</given-names></name><name><surname>Murali</surname><given-names>A</given-names></name><name><surname>Srinivas</surname><given-names>U</given-names></name><name><surname>Palaniswamy</surname><given-names>KR</given-names></name><name><surname>Srikumari</surname><given-names>D</given-names></name><name><surname>Thyagarajan</surname><given-names>SP</given-names></name></person-group><article-title>Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase test</article-title><source>J Med Microbiol</source><year>2007</year><volume>56</volume><fpage>1455</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">17965344</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name></person-group><article-title>Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment</article-title><source>Environ Health Perspect</source><year>2010</year><volume>118</volume><fpage>818</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">20172840</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besaratinia</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>SI</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name><name><surname>Pfeifer</surname><given-names>GP</given-names></name></person-group><article-title>In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>1127</fpage><lpage>1137, 1137.e1-1137.e5</lpage><pub-id pub-id-type="pmid">19524575</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>HI</given-names></name><name><surname>Wu</surname><given-names>HC</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Lu</surname><given-names>SN</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Jen</surname><given-names>CL</given-names></name><name><surname>You</surname><given-names>SL</given-names></name><name><surname>Santella</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name></person-group><article-title>Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers</article-title><source>Int J Cancer</source><year>2017</year><volume>141</volume><fpage>711</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">28509392</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>P</given-names></name></person-group><article-title>Risk factors for hepatocellular carcinoma in India</article-title><source>J Clin Exp Hepatol</source><year>2014</year><volume>4</volume><fpage>S34</fpage><lpage>S42</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottomley</surname><given-names>SS</given-names></name></person-group><article-title>Secondary iron overload disorders</article-title><source>Semin Hematol</source><year>1998</year><volume>35</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">9460811</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Kitano</surname><given-names>M</given-names></name><name><surname>Minami</surname><given-names>Y</given-names></name><name><surname>Suetomi</surname><given-names>Y</given-names></name><name><surname>Onda</surname><given-names>H</given-names></name></person-group><article-title>Hepatocellular carcinoma associated with secondary haemochromatosis in non-cirrhotic liver: a case report</article-title><source>Hepatol Res</source><year>2003</year><volume>26</volume><fpage>254</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">12850700</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikoma</surname><given-names>N</given-names></name><name><surname>Shinozaki</surname><given-names>H</given-names></name><name><surname>Kozuki</surname><given-names>A</given-names></name><name><surname>Ibuki</surname><given-names>S</given-names></name><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Mukai</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Ogata</surname><given-names>Y</given-names></name></person-group><article-title>A Case Report of Hepatocellular Carcinoma in a Non-cirrhotic Patient With Liver Iron Overload Associated With Myelodysplastic Syndrome</article-title><source>World J Oncol</source><year>2013</year><volume>4</volume><fpage>248</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">29147365</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turlin</surname><given-names>B</given-names></name><name><surname>Juguet</surname><given-names>F</given-names></name><name><surname>Moirand</surname><given-names>R</given-names></name><name><surname>Le Quilleuc</surname><given-names>D</given-names></name><name><surname>Lor&#x000e9;al</surname><given-names>O</given-names></name><name><surname>Campion</surname><given-names>JP</given-names></name><name><surname>Launois</surname><given-names>B</given-names></name><name><surname>Ram&#x000e9;e</surname><given-names>MP</given-names></name><name><surname>Brissot</surname><given-names>P</given-names></name><name><surname>Deugnier</surname><given-names>Y</given-names></name></person-group><article-title>Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver</article-title><source>Hepatology</source><year>1995</year><volume>22</volume><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">7635411</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>SP</given-names></name><name><surname>Raja</surname><given-names>K</given-names></name><name><surname>Amstad</surname><given-names>PA</given-names></name><name><surname>Sawyer</surname><given-names>M</given-names></name><name><surname>Trudel</surname><given-names>LJ</given-names></name><name><surname>Wogan</surname><given-names>GN</given-names></name><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Shields</surname><given-names>PG</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Hohler</surname><given-names>T</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Phillips</surname><given-names>DH</given-names></name><name><surname>Markin</surname><given-names>R</given-names></name><name><surname>Marrogi</surname><given-names>AJ</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><article-title>Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases</article-title><source>Proc Natl Acad Sci U S A</source><year>2000</year><volume>97</volume><fpage>12770</fpage><lpage>12775</lpage><pub-id pub-id-type="pmid">11050162</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannou</surname><given-names>GN</given-names></name><name><surname>Kowdley</surname><given-names>KV</given-names></name></person-group><article-title>Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen?</article-title><source>Clin Gastroenterol Hepatol</source><year>2003</year><volume>1</volume><fpage>246</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">15017663</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nzeako</surname><given-names>UC</given-names></name><name><surname>Goodman</surname><given-names>ZD</given-names></name><name><surname>Ishak</surname><given-names>KG</given-names></name></person-group><article-title>Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients</article-title><source>Am J Clin Pathol</source><year>1996</year><volume>105</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">8561091</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YJ</given-names></name></person-group><article-title>Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma</article-title><source>World J Hepatol</source><year>2010</year><volume>2</volume><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">21160980</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YS</given-names></name><name><surname>Chern</surname><given-names>HD</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Chang</surname><given-names>FY</given-names></name><name><surname>Lee</surname><given-names>SD</given-names></name></person-group><article-title>Polymorphism of the N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma</article-title><source>Am J Gastroenterol</source><year>2003</year><volume>98</volume><fpage>1417</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">12818290</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Tsai</surname><given-names>WY</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Feitelson</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Santella</surname><given-names>RM</given-names></name></person-group><article-title>4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls</article-title><source>Am J Epidemiol</source><year>1998</year><volume>147</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">9482507</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardt</surname><given-names>A</given-names></name><name><surname>Stippel</surname><given-names>D</given-names></name><name><surname>Odenthal</surname><given-names>M</given-names></name><name><surname>H&#x000f6;lscher</surname><given-names>AH</given-names></name><name><surname>Dienes</surname><given-names>HP</given-names></name><name><surname>Drebber</surname><given-names>U</given-names></name></person-group><article-title>Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: A case report</article-title><source>Case Rep Pathol</source><year>2012</year><volume>2012</volume><fpage>195607</fpage><pub-id pub-id-type="pmid">22934212</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solbach</surname><given-names>P</given-names></name><name><surname>Potthoff</surname><given-names>A</given-names></name><name><surname>Raatschen</surname><given-names>HJ</given-names></name><name><surname>Soudah</surname><given-names>B</given-names></name><name><surname>Lehmann</surname><given-names>U</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Gebel</surname><given-names>MJ</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name></person-group><article-title>Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report</article-title><source>BMC Gastroenterol</source><year>2015</year><volume>15</volume><fpage>60</fpage><pub-id pub-id-type="pmid">25986067</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DB</given-names></name><name><surname>Hall</surname><given-names>AB</given-names></name><name><surname>Michel</surname><given-names>M</given-names></name></person-group><article-title>Non-cirrhotic hepatocellular carcinoma in a young active duty male</article-title><source>Mil Med</source><year>2011</year><volume>176</volume><fpage>475</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">21539174</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiel</surname><given-names>MI</given-names></name><name><surname>Min</surname><given-names>A</given-names></name><name><surname>Gerber</surname><given-names>MA</given-names></name><name><surname>Faire</surname><given-names>B</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Thung</surname><given-names>SN</given-names></name></person-group><article-title>Hepatocellular carcinoma in long-term oral contraceptive use</article-title><source>Liver</source><year>1996</year><volume>16</volume><fpage>372</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">9021715</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name><name><surname>Nam</surname><given-names>DH</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name></person-group><article-title>A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male</article-title><source>Korean J Intern Med</source><year>2009</year><volume>24</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">19543495</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britto</surname><given-names>MR</given-names></name><name><surname>Thomas</surname><given-names>LA</given-names></name><name><surname>Balaratnam</surname><given-names>N</given-names></name><name><surname>Griffiths</surname><given-names>AP</given-names></name><name><surname>Duane</surname><given-names>PD</given-names></name></person-group><article-title>Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis</article-title><source>Scand J Gastroenterol</source><year>2000</year><volume>35</volume><fpage>889</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">10994630</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evert</surname><given-names>M</given-names></name><name><surname>Dombrowski</surname><given-names>F</given-names></name></person-group><article-title>[Hepatocellular carcinoma in the non-cirrhotic liver]</article-title><source>Pathologe</source><year>2008</year><volume>29</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">18057936</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiatt</surname><given-names>T</given-names></name><name><surname>Trotter</surname><given-names>JF</given-names></name><name><surname>Kam</surname><given-names>I</given-names></name></person-group><article-title>Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis</article-title><source>Am J Med Sci</source><year>2007</year><volume>334</volume><fpage>228</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">17873542</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;hler</surname><given-names>HH</given-names></name><name><surname>H&#x000f6;hler</surname><given-names>T</given-names></name><name><surname>K&#x000fc;sel</surname><given-names>U</given-names></name><name><surname>Kirkpatrick</surname><given-names>CJ</given-names></name><name><surname>Schirmacher</surname><given-names>P</given-names></name></person-group><article-title>Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report</article-title><source>Pathol Res Pract</source><year>1999</year><volume>195</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">10448668</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topic</surname><given-names>A</given-names></name><name><surname>Ljujic</surname><given-names>M</given-names></name><name><surname>Radojkovic</surname><given-names>D</given-names></name></person-group><article-title>Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma</article-title><source>Hepat Mon</source><year>2012</year><volume>12</volume><fpage>e7042</fpage><pub-id pub-id-type="pmid">23162602</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deybach</surname><given-names>JC</given-names></name><name><surname>Puy</surname><given-names>H</given-names></name></person-group><article-title>Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa</article-title><source>J Intern Med</source><year>2011</year><volume>269</volume><fpage>521</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">21323767</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luvai</surname><given-names>A</given-names></name><name><surname>Mbagaya</surname><given-names>W</given-names></name><name><surname>Narayanan</surname><given-names>D</given-names></name><name><surname>Degg</surname><given-names>T</given-names></name><name><surname>Toogood</surname><given-names>G</given-names></name><name><surname>Wyatt</surname><given-names>JI</given-names></name><name><surname>Swinson</surname><given-names>D</given-names></name><name><surname>Hall</surname><given-names>CJ</given-names></name><name><surname>Barth</surname><given-names>JH</given-names></name></person-group><article-title>Hepatocellular carcinoma in variegate porphyria: a case report and literature review</article-title><source>Ann Clin Biochem</source><year>2015</year><volume>52</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">25301776</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Fukui</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Tsujii</surname><given-names>T</given-names></name></person-group><article-title>Promoting effect of citrulline in hepatocarcinogenesis: possible mechanism in hypercitrullinemia</article-title><source>Hepatology</source><year>1990</year><volume>11</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">2347556</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukutomi</surname><given-names>K</given-names></name><name><surname>Sakamori</surname><given-names>R</given-names></name><name><surname>Furuta</surname><given-names>K</given-names></name><name><surname>Shigekawa</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Hikita</surname><given-names>H</given-names></name><name><surname>Yakushijin</surname><given-names>T</given-names></name><name><surname>Tatsumi</surname><given-names>T</given-names></name><name><surname>Honma</surname><given-names>K</given-names></name><name><surname>Morii</surname><given-names>E</given-names></name><name><surname>Takehara</surname><given-names>T</given-names></name></person-group><article-title>Hepatocellular carcinoma in a case of Wilson&#x02019;s disease with non-cirrhotic liver</article-title><source>Kanzo</source><year>2017</year><volume>58</volume><fpage>519</fpage><lpage>527</lpage></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thattil</surname><given-names>R</given-names></name><name><surname>Dufour</surname><given-names>JF</given-names></name></person-group><article-title>Hepatocellular carcinoma in a non-cirrhotic patient with Wilson's disease</article-title><source>World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>2110</fpage><lpage>2113</lpage><pub-id pub-id-type="pmid">23599633</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oterdoom</surname><given-names>LH</given-names></name><name><surname>Verweij</surname><given-names>KE</given-names></name><name><surname>Biermann</surname><given-names>K</given-names></name><name><surname>Langeveld</surname><given-names>M</given-names></name><name><surname>van Buuren</surname><given-names>HR</given-names></name></person-group><article-title>Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease</article-title><source>J Gastrointestin Liver Dis</source><year>2015</year><volume>24</volume><fpage>515</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">26697579</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krantz</surname><given-names>ID</given-names></name><name><surname>Piccoli</surname><given-names>DA</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name></person-group><article-title>Alagille syndrome</article-title><source>J Med Genet</source><year>1997</year><volume>34</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">9039994</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bail</surname><given-names>B</given-names></name><name><surname>Bioulac-Sage</surname><given-names>P</given-names></name><name><surname>Arnoux</surname><given-names>R</given-names></name><name><surname>Perissat</surname><given-names>J</given-names></name><name><surname>Saric</surname><given-names>J</given-names></name><name><surname>Balabaud</surname><given-names>C</given-names></name></person-group><article-title>Late recurrence of a hepatocellular carcinoma in a patient with incomplete Alagille syndrome</article-title><source>Gastroenterology</source><year>1990</year><volume>99</volume><fpage>1514</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">2170223</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fodor</surname><given-names>A</given-names></name><name><surname>Fit</surname><given-names>AM</given-names></name><name><surname>Farcau</surname><given-names>O</given-names></name><name><surname>Rusu</surname><given-names>I</given-names></name><name><surname>Stefanescu</surname><given-names>H</given-names></name><name><surname>Procopet</surname><given-names>B</given-names></name></person-group><article-title>A Rare Association between Left Lobe Secondary Biliary Cirrhosis and Budd-Chiari Syndrome Secondary to Hepatocellular Carcinoma in the Non-Cirrhotic Right Liver Lobe</article-title><source>J Gastrointestin Liver Dis</source><year>2017</year><volume>26</volume><fpage>421</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">29253059</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartleb</surname><given-names>M</given-names></name><name><surname>Gutkowski</surname><given-names>K</given-names></name><name><surname>Milkiewicz</surname><given-names>P</given-names></name></person-group><article-title>Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><fpage>1400</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">21472097</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donati</surname><given-names>B</given-names></name><name><surname>Pietrelli</surname><given-names>A</given-names></name><name><surname>Pingitore</surname><given-names>P</given-names></name><name><surname>Dongiovanni</surname><given-names>P</given-names></name><name><surname>Caddeo</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>Baselli</surname><given-names>G</given-names></name><name><surname>Pelusi</surname><given-names>S</given-names></name><name><surname>Rosso</surname><given-names>C</given-names></name><name><surname>Vanni</surname><given-names>E</given-names></name><name><surname>Daly</surname><given-names>A</given-names></name><name><surname>Mancina</surname><given-names>RM</given-names></name><name><surname>Grieco</surname><given-names>A</given-names></name><name><surname>Miele</surname><given-names>L</given-names></name><name><surname>Grimaudo</surname><given-names>S</given-names></name><name><surname>Craxi</surname><given-names>A</given-names></name><name><surname>Petta</surname><given-names>S</given-names></name><name><surname>De Luca</surname><given-names>L</given-names></name><name><surname>Maier</surname><given-names>S</given-names></name><name><surname>Soardo</surname><given-names>G</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Colli</surname><given-names>F</given-names></name><name><surname>Romagnoli</surname><given-names>R</given-names></name><name><surname>Anstee</surname><given-names>QM</given-names></name><name><surname>Reeves</surname><given-names>HL</given-names></name><name><surname>Fracanzani</surname><given-names>AL</given-names></name><name><surname>Fargion</surname><given-names>S</given-names></name><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Valenti</surname><given-names>L</given-names></name></person-group><article-title>Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease</article-title><source>Cancer Med</source><year>2017</year><volume>6</volume><fpage>1930</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">28677271</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farges</surname><given-names>O</given-names></name><name><surname>Dokmak</surname><given-names>S</given-names></name></person-group><article-title>Malignant transformation of liver adenoma: an analysis of the literature</article-title><source>Dig Surg</source><year>2010</year><volume>27</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">20357449</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoot</surname><given-names>JH</given-names></name><name><surname>Coelen</surname><given-names>RJ</given-names></name><name><surname>De Jong</surname><given-names>MC</given-names></name><name><surname>Dejong</surname><given-names>CH</given-names></name></person-group><article-title>Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases</article-title><source>HPB (Oxford)</source><year>2010</year><volume>12</volume><fpage>509</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">20887318</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>Malignant transformation of hepatocellular adenoma: How frequently does it happen?</article-title><source>Liver Cancer</source><year>2015</year><volume>4</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">26020024</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witjes</surname><given-names>CD</given-names></name><name><surname>Ten Kate</surname><given-names>FJ</given-names></name><name><surname>van Aalten</surname><given-names>SM</given-names></name><name><surname>Dwarkasing</surname><given-names>RS</given-names></name><name><surname>Willemssen</surname><given-names>FE</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name><name><surname>de Man</surname><given-names>RA</given-names></name><name><surname>Ijzermans</surname><given-names>JN</given-names></name></person-group><article-title>Hepatocellular adenoma as a risk factor for hepatocellular carcinoma in a non-cirrhotic liver: a plea against</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>1645</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">22535376</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>LM</given-names></name><name><surname>Rong</surname><given-names>WQ</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>WB</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>FQ</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>JX</given-names></name></person-group><article-title>Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers</article-title><source>Chin J Cancer</source><year>2015</year><volume>34</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">26058379</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cast&#x000e1;n</surname><given-names>A</given-names></name><name><surname>Navarro</surname><given-names>Y</given-names></name><name><surname>Sarr&#x000ed;a</surname><given-names>L</given-names></name><name><surname>Larrosa</surname><given-names>R</given-names></name><name><surname>Serradilla</surname><given-names>M</given-names></name><name><surname>Serrablo</surname><given-names>A</given-names></name></person-group><article-title>Radiological diagnosis of hepatocellular carcinoma in non-cirrhotic patients</article-title><source>Hepatoma Research</source><year>2017</year><volume>3</volume><fpage>1</fpage></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brancatelli</surname><given-names>G</given-names></name><name><surname>Federle</surname><given-names>MP</given-names></name><name><surname>Grazioli</surname><given-names>L</given-names></name><name><surname>Carr</surname><given-names>BI</given-names></name></person-group><article-title>Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents</article-title><source>Radiology</source><year>2002</year><volume>222</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11756710</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaddikeri</surname><given-names>S</given-names></name><name><surname>McNeeley</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>CL</given-names></name><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Dighe</surname><given-names>MK</given-names></name><name><surname>Yeh</surname><given-names>MM</given-names></name><name><surname>Dubinsky</surname><given-names>TJ</given-names></name><name><surname>Kolokythas</surname><given-names>O</given-names></name><name><surname>Lalwani</surname><given-names>N</given-names></name></person-group><article-title>Hepatocellular carcinoma in the noncirrhotic liver</article-title><source>AJR Am J Roentgenol</source><year>2014</year><volume>203</volume><fpage>W34</fpage><lpage>W47</lpage><pub-id pub-id-type="pmid">24951228</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>NB</given-names></name><name><surname>Jabbour</surname><given-names>SK</given-names></name><name><surname>Hon</surname><given-names>JD</given-names></name><name><surname>Berman</surname><given-names>JJ</given-names></name><name><surname>Malik</surname><given-names>D</given-names></name><name><surname>Carpizo</surname><given-names>D</given-names></name><name><surname>Moss</surname><given-names>RA</given-names></name></person-group><article-title>Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia: Case Report and Literature Review</article-title><source>J Clin Exp Hepatol</source><year>2015</year><volume>5</volume><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">26155045</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>MH</given-names></name><name><surname>Garcia</surname><given-names>RT</given-names></name><name><surname>Simpson</surname><given-names>PW</given-names></name><name><surname>Wright</surname><given-names>TL</given-names></name><name><surname>Keeffe</surname><given-names>EB</given-names></name></person-group><article-title>Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis</article-title><source>Hepatology</source><year>2002</year><volume>36</volume><fpage>410</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">12143050</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chagas</surname><given-names>AL</given-names></name><name><surname>Kikuchi</surname><given-names>L</given-names></name><name><surname>Herman</surname><given-names>P</given-names></name><name><surname>Alencar</surname><given-names>RS</given-names></name><name><surname>Tani</surname><given-names>CM</given-names></name><name><surname>Diniz</surname><given-names>MA</given-names></name><name><surname>Pugliese</surname><given-names>V</given-names></name><name><surname>Rocha Mde</surname><given-names>S</given-names></name><name><surname>D&#x02019;Albuquerque</surname><given-names>LA</given-names></name><name><surname>Carrilho</surname><given-names>FJ</given-names></name><name><surname>Alves</surname><given-names>VA</given-names></name></person-group><article-title>Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases</article-title><source>Clinics (Sao Paulo)</source><year>2015</year><volume>70</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">26017653</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassahun</surname><given-names>WT</given-names></name></person-group><article-title>Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments</article-title><source>World J Surg Oncol</source><year>2016</year><volume>14</volume><fpage>151</fpage><pub-id pub-id-type="pmid">27215576</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witjes</surname><given-names>CD</given-names></name><name><surname>Polak</surname><given-names>WG</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name><name><surname>Eskens</surname><given-names>FA</given-names></name><name><surname>Dwarkasing</surname><given-names>RS</given-names></name><name><surname>Verheij</surname><given-names>J</given-names></name><name><surname>de Man</surname><given-names>RA</given-names></name><name><surname>Ijzermans</surname><given-names>JN</given-names></name></person-group><article-title>Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers</article-title><source>Dig Surg</source><year>2012</year><volume>29</volume><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">23548745</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrero</surname><given-names>JA</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Nguyen</surname><given-names>MH</given-names></name><name><surname>Befeler</surname><given-names>AS</given-names></name><name><surname>Roberts</surname><given-names>LR</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Harnois</surname><given-names>D</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Normolle</surname><given-names>D</given-names></name><name><surname>Dalhgren</surname><given-names>J</given-names></name><name><surname>Chia</surname><given-names>D</given-names></name><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Wagner</surname><given-names>PD</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><article-title>Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">19362088</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CS</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Chiang</surname><given-names>MF</given-names></name><name><surname>Chen</surname><given-names>HS</given-names></name><name><surname>Lin</surname><given-names>TJ</given-names></name><name><surname>Liao</surname><given-names>LY</given-names></name></person-group><article-title>Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>6115</fpage><lpage>6119</lpage><pub-id pub-id-type="pmid">16273636</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakhary</surname><given-names>NI</given-names></name><name><surname>Khodeer</surname><given-names>SM</given-names></name><name><surname>Shafik</surname><given-names>HE</given-names></name><name><surname>Abdel Malak</surname><given-names>CA</given-names></name></person-group><article-title>Impact of PIVKA-II in diagnosis of hepatocellular carcinoma</article-title><source>J Adv Res</source><year>2013</year><volume>4</volume><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">25685463</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name></person-group><article-title>Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>90390</fpage><lpage>90401</lpage><pub-id pub-id-type="pmid">29163838</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ette</surname><given-names>AI</given-names></name><name><surname>Ndububa</surname><given-names>DA</given-names></name><name><surname>Adekanle</surname><given-names>O</given-names></name><name><surname>Ekrikpo</surname><given-names>U</given-names></name></person-group><article-title>Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study</article-title><source>BMC Gastroenterol</source><year>2015</year><volume>15</volume><fpage>113</fpage><pub-id pub-id-type="pmid">26341083</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winston</surname><given-names>CB</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name><name><surname>Panicek</surname><given-names>DM</given-names></name></person-group><article-title>Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers</article-title><source>Radiology</source><year>1999</year><volume>210</volume><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">9885590</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgio</surname><given-names>A</given-names></name><name><surname>Ferraioli</surname><given-names>G</given-names></name><name><surname>Tarantino</surname><given-names>L</given-names></name><name><surname>de Stefano</surname><given-names>G</given-names></name><name><surname>Scala</surname><given-names>V</given-names></name><name><surname>Scarano</surname><given-names>F</given-names></name><name><surname>Coppola</surname><given-names>C</given-names></name><name><surname>Del Viscovo</surname><given-names>L</given-names></name></person-group><article-title>Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance</article-title><source>AJR Am J Roentgenol</source><year>2004</year><volume>183</volume><fpage>1319</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">15505297</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Burns</surname><given-names>PN</given-names></name><name><surname>Wilson</surname><given-names>SR</given-names></name></person-group><article-title>Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation</article-title><source>Radiology</source><year>2007</year><volume>244</volume><fpage>898</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">17709836</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>HX</given-names></name><name><surname>Chen</surname><given-names>ZB</given-names></name><name><surname>Yang</surname><given-names>WP</given-names></name><name><surname>Zhao</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>LQ</given-names></name></person-group><article-title>Consistency analysis of contrast-enhanced ultrasound and contrast-enhanced CT in diagnosis of small hepatocellular carcinoma</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><fpage>21466</fpage><lpage>21471</lpage><pub-id pub-id-type="pmid">26885093</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>SR</given-names></name><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Jang</surname><given-names>HJ</given-names></name><name><surname>Burns</surname><given-names>PN</given-names></name></person-group><article-title>Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI</article-title><source>AJR Am J Roentgenol</source><year>2007</year><volume>189</volume><fpage>W7</fpage><lpage>W12</lpage><pub-id pub-id-type="pmid">17579140</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sp&#x000e2;rchez</surname><given-names>Z</given-names></name><name><surname>Radu</surname><given-names>P</given-names></name><name><surname>Kacso</surname><given-names>G</given-names></name><name><surname>Sp&#x000e2;rchez</surname><given-names>M</given-names></name><name><surname>Zaharia</surname><given-names>T</given-names></name><name><surname>Al Hajjar</surname><given-names>N</given-names></name></person-group><article-title>Prospective comparison between real time contrast enhanced and conventional ultrasound guidance in percutaneous biopsies of liver tumors</article-title><source>Med Ultrason</source><year>2015</year><volume>17</volume><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">26649339</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roccarina</surname><given-names>D</given-names></name><name><surname>Garcovich</surname><given-names>M</given-names></name><name><surname>Ainora</surname><given-names>ME</given-names></name><name><surname>Riccardi</surname><given-names>L</given-names></name><name><surname>Pompili</surname><given-names>M</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name><name><surname>Zocco</surname><given-names>MA</given-names></name></person-group><article-title>Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment</article-title><source>World J Hepatol</source><year>2015</year><volume>7</volume><fpage>1866</fpage><lpage>1874</lpage><pub-id pub-id-type="pmid">26207168</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Martino</surname><given-names>M</given-names></name><name><surname>Saba</surname><given-names>L</given-names></name><name><surname>Bosco</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>M</given-names></name><name><surname>Miles</surname><given-names>KA</given-names></name><name><surname>Di Miscio</surname><given-names>R</given-names></name><name><surname>Lombardo</surname><given-names>CV</given-names></name><name><surname>Tamponi</surname><given-names>E</given-names></name><name><surname>Piga</surname><given-names>M</given-names></name><name><surname>Catalano</surname><given-names>C</given-names></name></person-group><article-title>Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings</article-title><source>Eur Radiol</source><year>2014</year><volume>24</volume><fpage>1446</fpage><lpage>1454</lpage><pub-id pub-id-type="pmid">24770466</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafitte</surname><given-names>M</given-names></name><name><surname>Laurent</surname><given-names>V</given-names></name><name><surname>Soyer</surname><given-names>P</given-names></name><name><surname>Ayav</surname><given-names>A</given-names></name><name><surname>Balaj</surname><given-names>C</given-names></name><name><surname>Petit</surname><given-names>I</given-names></name><name><surname>Hossu</surname><given-names>G</given-names></name></person-group><article-title>MDCT features of hepatocellular carcinoma (HCC) in non-cirrhotic liver</article-title><source>Diagn Interv Imaging</source><year>2016</year><volume>97</volume><fpage>355</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">26546291</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shriki</surname><given-names>JE</given-names></name><name><surname>Seyal</surname><given-names>AR</given-names></name><name><surname>Dighe</surname><given-names>MK</given-names></name><name><surname>Yeh</surname><given-names>MM</given-names></name><name><surname>Jalikis</surname><given-names>FG</given-names></name><name><surname>Andeen</surname><given-names>NK</given-names></name><name><surname>Lall</surname><given-names>C</given-names></name><name><surname>Bhargava</surname><given-names>P</given-names></name></person-group><article-title>CT of Atypical and Uncommon Presentations of Hepatocellular Carcinoma</article-title><source>AJR Am J Roentgenol</source><year>2015</year><volume>205</volume><fpage>W411</fpage><lpage>W423</lpage><pub-id pub-id-type="pmid">26397348</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Federle</surname><given-names>MP</given-names></name><name><surname>Grazioli</surname><given-names>L</given-names></name><name><surname>Madariaga</surname><given-names>J</given-names></name><name><surname>Nalesnik</surname><given-names>M</given-names></name><name><surname>Marsh</surname><given-names>W</given-names></name></person-group><article-title>Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases</article-title><source>Radiology</source><year>1999</year><volume>213</volume><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">10551212</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLarney</surname><given-names>JK</given-names></name><name><surname>Rucker</surname><given-names>PT</given-names></name><name><surname>Bender</surname><given-names>GN</given-names></name><name><surname>Goodman</surname><given-names>ZD</given-names></name><name><surname>Kashitani</surname><given-names>N</given-names></name><name><surname>Ros</surname><given-names>PR</given-names></name></person-group><article-title>Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation</article-title><source>Radiographics</source><year>1999</year><volume>19</volume><fpage>453</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">10194790</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>MA</given-names></name><name><surname>Raptis</surname><given-names>DA</given-names></name><name><surname>Donati</surname><given-names>OF</given-names></name><name><surname>Hunziker</surname><given-names>R</given-names></name><name><surname>Schade</surname><given-names>E</given-names></name><name><surname>Sotiropoulos</surname><given-names>GC</given-names></name><name><surname>McCall</surname><given-names>J</given-names></name><name><surname>Bartlett</surname><given-names>A</given-names></name><name><surname>Bachellier</surname><given-names>P</given-names></name><name><surname>Frilling</surname><given-names>A</given-names></name><name><surname>Breitenstein</surname><given-names>S</given-names></name><name><surname>Clavien</surname><given-names>PA</given-names></name><name><surname>Alkadhi</surname><given-names>H</given-names></name><name><surname>Patak</surname><given-names>MA</given-names></name></person-group><article-title>MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation</article-title><source>Eur J Radiol</source><year>2015</year><volume>84</volume><fpage>1879</fpage><lpage>1887</lpage><pub-id pub-id-type="pmid">26194029</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attwa</surname><given-names>MH</given-names></name><name><surname>El-Etreby</surname><given-names>SA</given-names></name></person-group><article-title>Guide for diagnosis and treatment of hepatocellular carcinoma</article-title><source>World J Hepatol</source><year>2015</year><volume>7</volume><fpage>1632</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">26140083</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>D</given-names></name></person-group><article-title>Tissue diagnosis of hepatocellular carcinoma</article-title><source>J Clin Exp Hepatol</source><year>2014</year><volume>4</volume><fpage>S67</fpage><lpage>S73</lpage></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannapfel</surname><given-names>A</given-names></name><name><surname>Dienes</surname><given-names>HP</given-names></name><name><surname>Lohse</surname><given-names>AW</given-names></name></person-group><article-title>The indications for liver biopsy</article-title><source>Dtsch Arztebl Int</source><year>2012</year><volume>109</volume><fpage>477</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">22833761</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>F</given-names></name><name><surname>Fantini</surname><given-names>C</given-names></name><name><surname>Ratti</surname><given-names>F</given-names></name><name><surname>Lauro</surname><given-names>R</given-names></name><name><surname>Tranchart</surname><given-names>H</given-names></name><name><surname>Halls</surname><given-names>M</given-names></name><name><surname>Scuderi</surname><given-names>V</given-names></name><name><surname>Barkhatov</surname><given-names>L</given-names></name><name><surname>Edwin</surname><given-names>B</given-names></name><name><surname>Troisi</surname><given-names>RI</given-names></name><name><surname>Dagher</surname><given-names>I</given-names></name><name><surname>Reggiani</surname><given-names>P</given-names></name><name><surname>Belli</surname><given-names>G</given-names></name><name><surname>Aldrighetti</surname><given-names>L</given-names></name><name><surname>Abu Hilal</surname><given-names>M</given-names></name></person-group><article-title>Laparoscopic liver resections for hepatocellular carcinoma. Can we extend the surgical indication in cirrhotic patients?</article-title><source>Surg Endosc</source><year>2018</year><volume>32</volume><fpage>617</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">28717870</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>H</given-names></name><name><surname>Sotiropoulos</surname><given-names>GC</given-names></name><name><surname>D&#x000f6;mland</surname><given-names>M</given-names></name><name><surname>Fr&#x000fc;hauf</surname><given-names>NR</given-names></name><name><surname>Paul</surname><given-names>A</given-names></name><name><surname>H&#x000fc;sing</surname><given-names>J</given-names></name><name><surname>Malag&#x000f3;</surname><given-names>M</given-names></name><name><surname>Broelsch</surname><given-names>CE</given-names></name></person-group><article-title>Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis</article-title><source>Br J Surg</source><year>2005</year><volume>92</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15609381</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhoef</surname><given-names>C</given-names></name><name><surname>de Man</surname><given-names>RA</given-names></name><name><surname>Zondervan</surname><given-names>PE</given-names></name><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Tilanus</surname><given-names>HW</given-names></name><name><surname>Ijzermans</surname><given-names>JN</given-names></name></person-group><article-title>Good outcomes after resection of large hepatocellular carcinoma in the non-cirrhotic liver</article-title><source>Dig Surg</source><year>2004</year><volume>21</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">15523181</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Adair</surname><given-names>R</given-names></name><name><surname>Prasad</surname><given-names>KR</given-names></name><name><surname>Toogood</surname><given-names>GJ</given-names></name><name><surname>Lodge</surname><given-names>JP</given-names></name></person-group><article-title>Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes</article-title><source>J Am Coll Surg</source><year>2012</year><volume>214</volume><fpage>174</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">22137823</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>B</given-names></name></person-group><article-title>Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review</article-title><source>Surg Oncol</source><year>2014</year><volume>23</volume><fpage>236</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">25465529</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Waechter</surname><given-names>F</given-names></name><name><surname>Navarro</surname><given-names>F</given-names></name><name><surname>Abascal</surname><given-names>A</given-names></name><name><surname>Majno</surname><given-names>P</given-names></name><name><surname>Engerran</surname><given-names>L</given-names></name></person-group><article-title>Repeat hepatectomy for colorectal liver metastases</article-title><source>Ann Surg</source><year>1997</year><volume>225</volume><fpage>51</fpage><lpage>60; discussion 60-2</lpage><pub-id pub-id-type="pmid">8998120</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjittofi</surname><given-names>C</given-names></name><name><surname>Athanasopoulos</surname><given-names>PG</given-names></name><name><surname>Koti</surname><given-names>RS</given-names></name><name><surname>Konstantinidou</surname><given-names>SK</given-names></name><name><surname>Davidson</surname><given-names>BR</given-names></name></person-group><article-title>Long-term survival with repeated resections of recurrent hepatocellular carcinoma in a non-cirrhotic liver: case report and brief review of the literature</article-title><source>Ann Transl Med</source><year>2016</year><volume>4</volume><fpage>112</fpage><pub-id pub-id-type="pmid">27127765</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houben</surname><given-names>KW</given-names></name><name><surname>McCall</surname><given-names>JL</given-names></name></person-group><article-title>Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review</article-title><source>Liver Transpl Surg</source><year>1999</year><volume>5</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">10071346</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPeake</surname><given-names>JR</given-names></name><name><surname>O'Grady</surname><given-names>JG</given-names></name><name><surname>Zaman</surname><given-names>S</given-names></name><name><surname>Portmann</surname><given-names>B</given-names></name><name><surname>Wight</surname><given-names>DG</given-names></name><name><surname>Tan</surname><given-names>KC</given-names></name><name><surname>Calne</surname><given-names>RY</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name></person-group><article-title>Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome</article-title><source>J Hepatol</source><year>1993</year><volume>18</volume><fpage>226</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">7691926</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mergental</surname><given-names>H</given-names></name><name><surname>Porte</surname><given-names>RJ</given-names></name></person-group><article-title>Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis</article-title><source>Transpl Int</source><year>2010</year><volume>23</volume><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">20345561</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavien</surname><given-names>PA</given-names></name><name><surname>Lesurtel</surname><given-names>M</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Langer</surname><given-names>B</given-names></name><name><surname>Perrier</surname><given-names>A</given-names></name></person-group><collab>OLT for HCC Consensus Group</collab><article-title>Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><fpage>e11</fpage><lpage>e22</lpage><pub-id pub-id-type="pmid">22047762</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decaens</surname><given-names>T</given-names></name><name><surname>Laurent</surname><given-names>A</given-names></name><name><surname>Luciani</surname><given-names>A</given-names></name></person-group><article-title>Liver transplantation for hepatocellular carcinoma in non-cirrhotic livers regardless of the number and size of tumours?</article-title><source>J Hepatol</source><year>2012</year><volume>57</volume><fpage>235</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">22584453</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eatrides</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Kothari</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name></person-group><article-title>Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma</article-title><source>Cancer Control</source><year>2017</year><volume>24</volume><fpage>1073274817729243</fpage><pub-id pub-id-type="pmid">28975834</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>de Oliveira</surname><given-names>AC</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Bolondi</surname><given-names>L</given-names></name><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Borbath</surname><given-names>I</given-names></name><name><surname>H&#x000e4;ussinger</surname><given-names>D</given-names></name><name><surname>Giannaris</surname><given-names>T</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Moscovici</surname><given-names>M</given-names></name><name><surname>Voliotis</surname><given-names>D</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><collab>SHARP Investigators Study Group</collab><article-title>Sorafenib in advanced hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">18650514</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>SM</given-names></name><name><surname>Adnane</surname><given-names>L</given-names></name><name><surname>Newell</surname><given-names>P</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name></person-group><article-title>Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</article-title><source>Mol Cancer Ther</source><year>2008</year><volume>7</volume><fpage>3129</fpage><lpage>3140</lpage><pub-id pub-id-type="pmid">18852116</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mlynarsky</surname><given-names>L</given-names></name><name><surname>Menachem</surname><given-names>Y</given-names></name><name><surname>Shibolet</surname><given-names>O</given-names></name></person-group><article-title>Treatment of hepatocellular carcinoma: Steps forward but still a long way to go</article-title><source>World J Hepatol</source><year>2015</year><volume>7</volume><fpage>566</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">25848480</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Gouw</surname><given-names>AS</given-names></name><name><surname>van den Heuvel</surname><given-names>MC</given-names></name><name><surname>Molema</surname><given-names>G</given-names></name><name><surname>Poppema</surname><given-names>S</given-names></name><name><surname>van der Jagt</surname><given-names>EJ</given-names></name><name><surname>de Jong</surname><given-names>KP</given-names></name></person-group><article-title>Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>17</volume><fpage>1564</fpage><lpage>1571</lpage><pub-id pub-id-type="pmid">20087783</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><collab>Nivolumab Approved for Liver Cancer</collab><source>Cancer Discov</source><year>2017</year><volume>7</volume><fpage>OF3</fpage></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Merle</surname><given-names>P</given-names></name><name><surname>Granito</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><name><surname>Pracht</surname><given-names>M</given-names></name><name><surname>Yokosuka</surname><given-names>O</given-names></name><name><surname>Rosmorduc</surname><given-names>O</given-names></name><name><surname>Breder</surname><given-names>V</given-names></name><name><surname>Gerolami</surname><given-names>R</given-names></name><name><surname>Masi</surname><given-names>G</given-names></name><name><surname>Ross</surname><given-names>PJ</given-names></name><name><surname>Song</surname><given-names>T</given-names></name><name><surname>Bronowicki</surname><given-names>JP</given-names></name><name><surname>Ollivier-Hourmand</surname><given-names>I</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>LeBerre</surname><given-names>MA</given-names></name><name><surname>Baumhauer</surname><given-names>A</given-names></name><name><surname>Meinhardt</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>G</given-names></name></person-group><collab>RESORCE Investigators</collab><article-title>Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">27932229</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>O</given-names></name><name><surname>Truant</surname><given-names>S</given-names></name><name><surname>Sergent-Baudson</surname><given-names>G</given-names></name><name><surname>Comet</surname><given-names>B</given-names></name><name><surname>Pruvot</surname><given-names>FR</given-names></name><name><surname>Hebbar</surname><given-names>M</given-names></name></person-group><article-title>Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: report of three cases</article-title><source>J Chemother</source><year>2008</year><volume>20</volume><fpage>518</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">18676236</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samonakis</surname><given-names>DN</given-names></name><name><surname>Kouroumalis</surname><given-names>EA</given-names></name></person-group><article-title>Systemic treatment for hepatocellular carcinoma: Still unmet expectations</article-title><source>World J Hepatol</source><year>2017</year><volume>9</volume><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">28144389</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edeline</surname><given-names>J</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Vauleon</surname><given-names>E</given-names></name><name><surname>Guillygomac'h</surname><given-names>A</given-names></name><name><surname>Boudjema</surname><given-names>K</given-names></name><name><surname>Boucher</surname><given-names>E</given-names></name></person-group><article-title>Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study</article-title><source>World J Gastroenterol</source><year>2009</year><volume>15</volume><fpage>713</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">19222095</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gras</surname><given-names>P</given-names></name><name><surname>Truant</surname><given-names>S</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><name><surname>Ladrat</surname><given-names>L</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Pruvot</surname><given-names>FR</given-names></name><name><surname>Hebbar</surname><given-names>M</given-names></name></person-group><article-title>Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma</article-title><source>Case Rep Oncol</source><year>2012</year><volume>5</volume><fpage>169</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">22666208</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Invernizzi</surname><given-names>F</given-names></name><name><surname>Iavarone</surname><given-names>M</given-names></name><name><surname>Donato</surname><given-names>MF</given-names></name><name><surname>Sangiovanni</surname><given-names>A</given-names></name><name><surname>Monico</surname><given-names>S</given-names></name><name><surname>Manini</surname><given-names>MA</given-names></name><name><surname>Maggi</surname><given-names>U</given-names></name><name><surname>Antonelli</surname><given-names>B</given-names></name><name><surname>Dondossola</surname><given-names>D</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Lampertico</surname><given-names>P</given-names></name></person-group><article-title>Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival</article-title><source>Digest Liver Dis</source><year>2018</year><volume>50</volume><fpage>49</fpage></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>LR</given-names></name><name><surname>Hostetter</surname><given-names>RB</given-names></name><name><surname>Ressler</surname><given-names>B</given-names></name><name><surname>Bowser</surname><given-names>I</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Vaghefi</surname><given-names>H</given-names></name><name><surname>Abad</surname><given-names>J</given-names></name><name><surname>Gulec</surname><given-names>S</given-names></name><name><surname>Schwarz</surname><given-names>RE</given-names></name></person-group><article-title>Liver resection for metastatic disease after y90 radioembolization: a case series with long-term follow-up</article-title><source>Ann Surg Oncol</source><year>2015</year><volume>22</volume><fpage>467</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">25190114</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mafeld</surname><given-names>S</given-names></name><name><surname>French</surname><given-names>J</given-names></name><name><surname>Tiniakos</surname><given-names>D</given-names></name><name><surname>Haugk</surname><given-names>B</given-names></name><name><surname>Manas</surname><given-names>D</given-names></name><name><surname>Littler</surname><given-names>P</given-names></name></person-group><article-title>Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection</article-title><source>Cardiovasc Intervent Radiol</source><year>2018</year><volume>41</volume><fpage>816</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">29468286</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnaoutakis</surname><given-names>DJ</given-names></name><name><surname>Mavros</surname><given-names>MN</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Alexandrescu</surname><given-names>S</given-names></name><name><surname>Firoozmand</surname><given-names>A</given-names></name><name><surname>Popescu</surname><given-names>I</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Choti</surname><given-names>MA</given-names></name><name><surname>Pawlik</surname><given-names>TM</given-names></name></person-group><article-title>Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis</article-title><source>Ann Surg Oncol</source><year>2014</year><volume>21</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">23959056</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e8;ge</surname><given-names>T</given-names></name><name><surname>Le Treut</surname><given-names>YP</given-names></name><name><surname>Hardwigsen</surname><given-names>J</given-names></name><name><surname>Ananian</surname><given-names>P</given-names></name><name><surname>Richa</surname><given-names>H</given-names></name><name><surname>Campan</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>S</given-names></name></person-group><article-title>Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series</article-title><source>J Gastrointest Surg</source><year>2007</year><volume>11</volume><fpage>619</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">17468920</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>Chan</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>CF</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Eldeen</surname><given-names>FZ</given-names></name><name><surname>Chou</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Chen</surname><given-names>MF</given-names></name></person-group><article-title>Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence?</article-title><source>J Gastrointest Surg</source><year>2011</year><volume>15</volume><fpage>1440</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">21541770</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Kaseb</surname><given-names>AO</given-names></name><name><surname>Aloia</surname><given-names>TA</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Hassan</surname><given-names>MM</given-names></name><name><surname>Passot</surname><given-names>G</given-names></name><name><surname>Raghav</surname><given-names>KP</given-names></name><name><surname>Shama</surname><given-names>MA</given-names></name><name><surname>Chun</surname><given-names>YS</given-names></name></person-group><article-title>Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma</article-title><source>J Gastrointest Surg</source><year>2016</year><volume>20</volume><fpage>1725</fpage><lpage>1731</lpage><pub-id pub-id-type="pmid">27456016</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>NP</given-names></name><name><surname>Dunki-Jacobs</surname><given-names>EM</given-names></name><name><surname>Callender</surname><given-names>GG</given-names></name><name><surname>Anderson</surname><given-names>RJ</given-names></name><name><surname>Scoggins</surname><given-names>CR</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Martin</surname><given-names>RC</given-names></name></person-group><article-title>Evaluation of alpha-fetoprotein staging system for hepatocellular carcinoma in noncirrhotic patients</article-title><source>Am Surg</source><year>2013</year><volume>79</volume><fpage>716</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">23816006</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Hann</surname><given-names>HW</given-names></name><name><surname>Myers</surname><given-names>RE</given-names></name><name><surname>Hann</surname><given-names>RS</given-names></name><name><surname>Au</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Xing</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><article-title>Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>1014</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">22444598</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YK</given-names></name><name><surname>Bi</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>ZY</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Zhou</surname><given-names>JG</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>YF</given-names></name><name><surname>Li</surname><given-names>MX</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>XL</given-names></name><name><surname>Mao</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>XH</given-names></name><name><surname>Hu</surname><given-names>HJ</given-names></name><name><surname>Liu</surname><given-names>JM</given-names></name><name><surname>Cai</surname><given-names>JQ</given-names></name></person-group><article-title>[A new prognostic score system of hepatocellular carcinoma following hepatectomy]</article-title><source>Zhonghua Zhong Liu Za Zhi</source><year>2017</year><volume>39</volume><fpage>903</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">29262506</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambros</surname><given-names>V</given-names></name></person-group><article-title>The functions of animal microRNAs</article-title><source>Nature</source><year>2004</year><volume>431</volume><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">15372042</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasuri</surname><given-names>F</given-names></name><name><surname>Visani</surname><given-names>M</given-names></name><name><surname>Acquaviva</surname><given-names>G</given-names></name><name><surname>Brand</surname><given-names>T</given-names></name><name><surname>Fiorentino</surname><given-names>M</given-names></name><name><surname>Pession</surname><given-names>A</given-names></name><name><surname>Tallini</surname><given-names>G</given-names></name><name><surname>D'Errico</surname><given-names>A</given-names></name><name><surname>de Biase</surname><given-names>D</given-names></name></person-group><article-title>Role of microRNAs in the main molecular pathways of hepatocellular carcinoma</article-title><source>World J Gastroenterol</source><year>2018</year><volume>24</volume><fpage>2647</fpage><lpage>2660</lpage><pub-id pub-id-type="pmid">29991871</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name></person-group><article-title>Influence of microRNA on the maintenance of human iron metabolism</article-title><source>Nutrients</source><year>2013</year><volume>5</volume><fpage>2611</fpage><lpage>2628</lpage><pub-id pub-id-type="pmid">23846788</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>CM</given-names></name><name><surname>Varley</surname><given-names>RB</given-names></name><name><surname>Lawless</surname><given-names>MW</given-names></name></person-group><article-title>MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled</article-title><source>World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>5212</fpage><lpage>5226</lpage><pub-id pub-id-type="pmid">23983424</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>L-H</given-names></name><name><surname>Kim</surname><given-names>H-S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>BA</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>SY</given-names></name><name><surname>Cho</surname><given-names>CK</given-names></name></person-group><article-title>Dysregulated microRNAs in non-cirrhotic hepatocellular carcinoma</article-title><source>Genes Genom</source><year>2013</year><volume>35</volume><fpage>759</fpage><lpage>765</lpage></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>L</given-names></name></person-group><article-title>Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma</article-title><source>Medicine (Baltimore)</source><year>2017</year><volume>96</volume><fpage>e5642</fpage><pub-id pub-id-type="pmid">28079796</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Arizumi</surname><given-names>T</given-names></name><name><surname>Hagiwara</surname><given-names>S</given-names></name><name><surname>Ida</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma</article-title><source>Liver Cancer</source><year>2017</year><volume>6</volume><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">28275578</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>YB</given-names></name></person-group><article-title>Identifying Differentially Expressed MicroRNAs Between Cirrhotic and Non-Cirrhotic Hepatocellular Carcinoma and Exploring Their Functions Using Bioinformatic Analysis</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>48</volume><fpage>1443</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">30064138</pub-id></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Liang</surname><given-names>KH</given-names></name><name><surname>Chien</surname><given-names>RN</given-names></name><name><surname>Hu</surname><given-names>TH</given-names></name><name><surname>Lin</surname><given-names>KH</given-names></name><name><surname>Hsu</surname><given-names>CW</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Pan</surname><given-names>TL</given-names></name><name><surname>Ke</surname><given-names>PY</given-names></name><name><surname>Yeh</surname><given-names>CT</given-names></name></person-group><article-title>A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>523</fpage><pub-id pub-id-type="pmid">28364124</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Techathuvanan</surname><given-names>K</given-names></name><name><surname>Srisajjakul</surname><given-names>S</given-names></name><name><surname>Pongpaibul</surname><given-names>A</given-names></name><name><surname>Limsrichamrern</surname><given-names>S</given-names></name><name><surname>Charatcharoenwitthaya</surname><given-names>P</given-names></name><name><surname>Chainuvati</surname><given-names>S</given-names></name><name><surname>Tanwandee</surname><given-names>T</given-names></name><name><surname>Chotiyaputta</surname><given-names>W</given-names></name></person-group><article-title>Comparison between disease free survival of hepatocellular carcinoma after hepatic resection in chronic hepatitis B patients with or without cirrhosis</article-title><source>J Med Assoc Thai</source><year>2015</year><volume>98</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">25958707</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Chau</surname><given-names>GY</given-names></name><name><surname>Lui</surname><given-names>WY</given-names></name><name><surname>Tsay</surname><given-names>SH</given-names></name><name><surname>King</surname><given-names>KL</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name></person-group><article-title>Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver</article-title><source>Arch Surg</source><year>2004</year><volume>139</volume><fpage>320</fpage><lpage>325; discussion 326</lpage><pub-id pub-id-type="pmid">15006892</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grazi</surname><given-names>GL</given-names></name><name><surname>Cescon</surname><given-names>M</given-names></name><name><surname>Ravaioli</surname><given-names>M</given-names></name><name><surname>Ercolani</surname><given-names>G</given-names></name><name><surname>Gardini</surname><given-names>A</given-names></name><name><surname>Del Gaudio</surname><given-names>M</given-names></name><name><surname>Vetrone</surname><given-names>G</given-names></name><name><surname>Cavallari</surname><given-names>A</given-names></name></person-group><article-title>Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>17 Suppl 2</volume><fpage>119</fpage><lpage>129</lpage></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kew</surname><given-names>MC</given-names></name></person-group><article-title>Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks</article-title><source>Gastroenterology</source><year>1989</year><volume>97</volume><fpage>136</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">2470634</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albeldawi</surname><given-names>M</given-names></name><name><surname>Soliman</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Zein</surname><given-names>NN</given-names></name></person-group><article-title>Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients</article-title><source>Dig Dis Sci</source><year>2012</year><volume>57</volume><fpage>3265</fpage><lpage>3270</lpage><pub-id pub-id-type="pmid">22695885</pub-id></element-citation></ref></ref-list></back></article>